<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>JINTELI- norethindrone acetate and ethinyl estradiol tablet </strong><br>Teva Pharmaceuticals USA Inc<br></p></div>
<div id="Highlights" class="Highlights"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1>HIGHLIGHTS OF PRESCRIBING INFORMATION</h1>
<div class="HighlightsDisclaimer">These highlights do not include all the information needed to use Jinteli<span class="Sup">® </span>safely and effectively.  See full prescribing information for Jinteli<span class="Sup">®</span>.<br><br>Jinteli<span class="Sup">®</span> (norethindrone acetate and ethinyl estradiol tablets USP)<br>Initial U.S. Approval: 1968</div>
<div class="Warning"><div>
<h1 class="Warning">WARNING: <span class="product-label-link" type="condition" conceptid="134057" conceptname="Disorder of cardiovascular system">CARDIOVASCULAR DISORDERS</span>, BREAST CANCER, ENDOMETRIAL CANCER AND PROBABLE <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">DEMENTIA</span></h1>
<h1 class="Warning"><span class="Italics">See full prescribing information for complete boxed warning.</span></h1>
<p class="Highlighta"><span class="Bold">Estrogen Plus Progestin Therapy </span> </p>
<dl>
<dt>•</dt>
<dd><span class="Bold">Estrogen plus progestin therapy should not be used for the prevention of cardiovascular disease or <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">dementia</span> (<a href="#ID_37d6c252-eb1b-49ec-b65d-5be3dfa48a29">5.1</a>, <a href="#ID_b6c93caa-3b1a-4955-93b6-2c1d7d79d3e1">5.3</a>)</span></dd>
<dt>•</dt>
<dd><span class="Bold">The Women’s Health Initiative (WHI) estrogen plus progestin substudy reported increased risks of <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span>, <span class="product-label-link" type="condition" conceptid="4042396" conceptname="Deep thrombophlebitis">deep vein thrombosis</span> (DVT), <span class="product-label-link" type="condition" conceptid="440417" conceptname="Pulmonary embolism">pulmonary embolism</span> (PE), and <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span> (MI) (<a href="#ID_37d6c252-eb1b-49ec-b65d-5be3dfa48a29">5.1</a>)</span></dd>
<dt>•</dt>
<dd><span class="Bold">The WHI estrogen plus progestin substudy reported an increased risk of invasive breast cancer (<a href="#ID_08fd3295-48f2-4e90-b7ac-6b8a20dfa6fc">5.2</a>)</span></dd>
<dt>•</dt>
<dd><span class="Bold">The WHI Memory Study (WHIMS) estrogen plus progestin ancillary study of WHI reported an increased risk probable <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">dementia</span> in postmenopausal women 65 years of age and older (<a href="#ID_b6c93caa-3b1a-4955-93b6-2c1d7d79d3e1">5.3</a>)</span></dd>
</dl>
<p class="Highlighta"><span class="Bold">Estrogen-Alone Therapy </span> </p>
<dl>
<dt>•</dt>
<dd><span class="Bold">There is an increased risk of endometrial cancer in a woman with a uterus who uses unopposed estrogens (<a href="#ID_08fd3295-48f2-4e90-b7ac-6b8a20dfa6fc">5.2</a>)</span></dd>
<dt>•</dt>
<dd><span class="Bold">Estrogen-alone therapy should not be used for the prevention of cardiovascular disease or <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">dementia</span> (<a href="#ID_37d6c252-eb1b-49ec-b65d-5be3dfa48a29">5.1</a>, <a href="#ID_b6c93caa-3b1a-4955-93b6-2c1d7d79d3e1">5.3</a>)</span></dd>
<dt>•</dt>
<dd><span class="Bold">The WHI estrogen-alone substudy reported increased risks of <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span> and DVT (<a href="#ID_37d6c252-eb1b-49ec-b65d-5be3dfa48a29">5.1</a>)</span></dd>
<dt>•</dt>
<dd><span class="Bold">The WHIMS estrogen-alone ancillary study of WHI reported an increased risk of probable <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">dementia</span> in postmenopausal women 65 years of age and older (<a href="#ID_b6c93caa-3b1a-4955-93b6-2c1d7d79d3e1">5.3</a>)</span></dd>
</dl>
</div></div>
<div class="HighlightSection">
<h1 class="Highlights"><span>RECENT MAJOR CHANGES</span></h1>
<div>
<p class="Highlighta"> </p>
<table width="100%">
<col width="83%">
<col width="18%">
<tbody class="Headless">
<tr class="First Toprule">
<td><p class="Highlighta">Contraindications (<a href="#ID_a47e2a7b-c689-4deb-a20b-615691f468ac">4</a>) </p></td>
<td align="right"><p class="Highlighta">1/2014    </p></td>
</tr>
<tr class="Botrule Last">
<td><p class="Highlighta">Warnings and Precautions, <span class="product-label-link" type="condition" conceptid="4307793" conceptname="Hereditary angioedema">Hereditary Angioedema</span> (<a href="#ID_1ea76bb3-9e99-48bc-a165-6ae1c544e3e4">5.15</a>) </p></td>
<td align="right"><p class="Highlighta">1/2014 </p></td>
</tr>
</tbody>
</table>
</div>
</div>
<div></div>
<div class="Warning"><div>
<h1 class="Warning">WARNING: <span class="product-label-link" type="condition" conceptid="134057" conceptname="Disorder of cardiovascular system">CARDIOVASCULAR DISORDERS</span>, BREAST CANCER, ENDOMETRIAL CANCER AND PROBABLE <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">DEMENTIA</span></h1>
<h1 class="Warning"><span class="Italics">See full prescribing information for complete boxed warning.</span></h1>
<p class="Highlighta"><span class="Bold">Estrogen Plus Progestin Therapy </span> </p>
<dl>
<dt>•</dt>
<dd><span class="Bold">Estrogen plus progestin therapy should not be used for the prevention of cardiovascular disease or <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">dementia</span> (<a href="#ID_37d6c252-eb1b-49ec-b65d-5be3dfa48a29">5.1</a>, <a href="#ID_b6c93caa-3b1a-4955-93b6-2c1d7d79d3e1">5.3</a>)</span></dd>
<dt>•</dt>
<dd><span class="Bold">The Women’s Health Initiative (WHI) estrogen plus progestin substudy reported increased risks of <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span>, <span class="product-label-link" type="condition" conceptid="4042396" conceptname="Deep thrombophlebitis">deep vein thrombosis</span> (DVT), <span class="product-label-link" type="condition" conceptid="440417" conceptname="Pulmonary embolism">pulmonary embolism</span> (PE), and <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span> (MI) (<a href="#ID_37d6c252-eb1b-49ec-b65d-5be3dfa48a29">5.1</a>)</span></dd>
<dt>•</dt>
<dd><span class="Bold">The WHI estrogen plus progestin substudy reported an increased risk of invasive breast cancer (<a href="#ID_08fd3295-48f2-4e90-b7ac-6b8a20dfa6fc">5.2</a>)</span></dd>
<dt>•</dt>
<dd><span class="Bold">The WHI Memory Study (WHIMS) estrogen plus progestin ancillary study of WHI reported an increased risk probable <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">dementia</span> in postmenopausal women 65 years of age and older (<a href="#ID_b6c93caa-3b1a-4955-93b6-2c1d7d79d3e1">5.3</a>)</span></dd>
</dl>
<p class="Highlighta"><span class="Bold">Estrogen-Alone Therapy </span> </p>
<dl>
<dt>•</dt>
<dd><span class="Bold">There is an increased risk of endometrial cancer in a woman with a uterus who uses unopposed estrogens (<a href="#ID_08fd3295-48f2-4e90-b7ac-6b8a20dfa6fc">5.2</a>)</span></dd>
<dt>•</dt>
<dd><span class="Bold">Estrogen-alone therapy should not be used for the prevention of cardiovascular disease or <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">dementia</span> (<a href="#ID_37d6c252-eb1b-49ec-b65d-5be3dfa48a29">5.1</a>, <a href="#ID_b6c93caa-3b1a-4955-93b6-2c1d7d79d3e1">5.3</a>)</span></dd>
<dt>•</dt>
<dd><span class="Bold">The WHI estrogen-alone substudy reported increased risks of <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span> and DVT (<a href="#ID_37d6c252-eb1b-49ec-b65d-5be3dfa48a29">5.1</a>)</span></dd>
<dt>•</dt>
<dd><span class="Bold">The WHIMS estrogen-alone ancillary study of WHI reported an increased risk of probable <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">dementia</span> in postmenopausal women 65 years of age and older (<a href="#ID_b6c93caa-3b1a-4955-93b6-2c1d7d79d3e1">5.3</a>)</span></dd>
</dl>
</div></div>
<div class="HighlightSection">
<h1 class="Highlights"><span>INDICATIONS AND USAGE</span></h1>
<div>
<p class="Highlighta">Jinteli<span class="Bold"><span class="Italics"></span></span>is an estrogen plus progestin indicated in a woman with a uterus for:  </p>
<dl>
<dt>•</dt>
<dd>Treatment of Moderate to Severe Vasomotor Symptoms due to <span class="product-label-link" type="condition" conceptid="4059477" conceptname="Menopause">Menopause</span> (<a href="#ID_dfd16e8f-b7b7-431f-bafa-e6442320b188">1.1</a>)</dd>
<dt>•</dt>
<dd> Prevention of Postmenopausal <span class="product-label-link" type="condition" conceptid="80502" conceptname="Osteoporosis">Osteoporosis</span> (<a href="#ID_7b0c4c37-83bf-422b-90a6-e2746645ba9a">1.2</a>)</dd>
</dl>
</div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE AND ADMINISTRATION</span></h1>
<div><dl>
<dt>•</dt>
<dd>One tablet taken orally once daily (<a href="#ID_204cd19a-bfea-4963-9f3d-c6978d48cfa7">2.1</a>, <a href="#ID_eb02fa37-db59-4599-94dc-0b76df45bdf0">2.2</a>)</dd>
</dl></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE FORMS AND STRENGTHS</span></h1>
<div><dl>
<dt>•</dt>
<dd>White, round, flat-faced, beveled edge, unscored tablet contains 1 mg norethindrone acetate and 5 mcg ethinyl estradiol (<a href="#ID_057c7afa-7fcc-4339-ae40-aa8b33f229da">3</a>)</dd>
</dl></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>CONTRAINDICATIONS</span></h1>
<div><dl>
<dt>•</dt>
<dd>Undiagnosed abnormal genital <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> (<a href="#ID_a47e2a7b-c689-4deb-a20b-615691f468ac">4</a>)</dd>
<dt>•</dt>
<dd>   Known, suspected, or history of breast cancer (<a href="#ID_a47e2a7b-c689-4deb-a20b-615691f468ac">4</a>, <a href="#ID_08fd3295-48f2-4e90-b7ac-6b8a20dfa6fc">5.2</a>)</dd>
<dt>•</dt>
<dd>   Known or suspected estrogen-dependent neoplasia (<a href="#ID_a47e2a7b-c689-4deb-a20b-615691f468ac">4</a>, <a href="#ID_08fd3295-48f2-4e90-b7ac-6b8a20dfa6fc">5.2</a>)</dd>
<dt>•</dt>
<dd>   Active DVT, PE or a history of these conditions (<a href="#ID_a47e2a7b-c689-4deb-a20b-615691f468ac">4</a>, <a href="#ID_37d6c252-eb1b-49ec-b65d-5be3dfa48a29">5.1</a>)</dd>
<dt>•</dt>
<dd>   Active arterial thromboembolic disease (for example, <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span> and MI), or a history of these conditions (<a href="#ID_a47e2a7b-c689-4deb-a20b-615691f468ac">4</a>, <a href="#ID_37d6c252-eb1b-49ec-b65d-5be3dfa48a29">5.1</a>) </dd>
<dt>•</dt>
<dd>   Known <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylactic reaction</span> or <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioedema</span> to Jinteli<span class="Bold"><span class="Italics"></span></span>(<a href="#ID_a47e2a7b-c689-4deb-a20b-615691f468ac">4</a>)</dd>
<dt>•</dt>
<dd>   Known liver impairment or disease (<a href="#ID_a47e2a7b-c689-4deb-a20b-615691f468ac">4</a>, <a href="#ID_ae25c714-c08c-4900-99c9-c2613eac6bd7">5.10</a>)</dd>
<dt>•</dt>
<dd>   Known protein C, protein S, or antithrombin deficiency, or other known thrombophilic disorders (<a href="#ID_a47e2a7b-c689-4deb-a20b-615691f468ac">4</a>)</dd>
<dt>•</dt>
<dd>   Known or suspected pregnancy (<a href="#ID_a47e2a7b-c689-4deb-a20b-615691f468ac">4</a>, <a href="#ID_4755eb47-0714-4f8d-8d9f-27d3becaebea">8.1</a>)</dd>
</dl></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>WARNINGS AND PRECAUTIONS</span></h1>
<div><dl>
<dt>•</dt>
<dd>Estrogens increase the risk of <span class="product-label-link" type="condition" conceptid="192353" conceptname="Disorder of gallbladder">gallbladder disease</span> (<a href="#ID_6a327e5a-d4ae-475a-a1cd-2f781f95a52e">5.4</a>)</dd>
<dt>•</dt>
<dd>Discontinue estrogen if severe <span class="product-label-link" type="condition" conceptid="435511" conceptname="Hypercalcemia">hypercalcemia</span>, <span class="product-label-link" type="condition" conceptid="377551" conceptname="Blind hypertensive eye">loss of vision</span>, severe <span class="product-label-link" type="condition" conceptid="440360" conceptname="Pure hyperglyceridemia">hypertriglyceridemia</span> or <span class="product-label-link" type="condition" conceptid="4185719" conceptname="Cholestatic jaundice syndrome">cholestatic jaundice</span> occurs (<a href="#ID_5c282fda-1f30-4808-9fbb-a36514600815">5.5</a>, <a href="#ID_416fdc25-421d-464d-8381-a6bfcf83f19b">5.6</a>, <a href="#ID_8f8118b7-8533-4f57-9940-4f0424dead4c">5.9</a>, <a href="#ID_ae25c714-c08c-4900-99c9-c2613eac6bd7">5.10</a>)</dd>
<dt>•</dt>
<dd>Monitor thyroid function in women on thyroid replacement therapy (<a href="#ID_a820852e-e18a-455c-94ca-175660fac50e">5.11</a>, <a href="#ID_d3e1ee6a-160c-4179-976f-b432492c4148">5.18</a>)</dd>
</dl></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>ADVERSE REACTIONS</span></h1>
<div>
<p class="Highlighta">Most common adverse reactions (incidence greater than or equal to 5 percent) are <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span>, <span class="product-label-link" type="condition" conceptid="73819" conceptname="Pain of breast">breast pain</span>, and <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span> (generalized). (<a href="#ID_0a4464a2-1af2-464e-bb8e-1e37f12a6406">6.1</a>) </p>
<p class="Highlighta">To report SUSPECTED ADVERSE REACTIONS, contact TEVA USA, PHARMACOVIGILANCE at 1-866-832-8537 or drug.safety@tevapharm.com; or FDA at 1-800-FDA-1088 or <a href="http://www.fda.gov/medwatch">www.fda.gov/medwatch.</a> </p>
</div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DRUG INTERACTIONS</span></h1>
<div><dl>
<dt>•</dt>
<dd>Inducers and/or inhibitors of CYP3A4 may affect estrogen drug metabolism (<a href="#ID_d43d14ee-8fff-46f2-bf5f-7c8dfea877e1">7.1</a>)</dd>
</dl></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>USE IN SPECIFIC POPULATIONS</span></h1>
<div><dl>
<dt>•</dt>
<dd>Nursing Mothers: Estrogen administration to nursing women has been shown to decrease the quantity and quality of    breast milk (<a href="#ID_c4c70d50-91ed-4a1b-a31c-08c3ab2ac37b">8.3</a>)</dd>
<dt>•</dt>
<dd>Geriatric Use: An increased risk of probable <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">dementia</span> in women over 65 years of age was reported in the Women’s  Health Initiative Memory ancillary studies of the Women’s Health Initiative (<a href="#ID_b6c93caa-3b1a-4955-93b6-2c1d7d79d3e1">5.3</a>, <a href="#ID_047b0de5-d7ac-4eb7-b76b-3d20764b0a03">8.5</a>) </dd>
</dl></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<div>
<div></div>
<div></div>
<div></div>
</div>
<div><div></div></div>
<div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
<div>
<div></div>
<div></div>
</div>
<div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<div><div></div></div>
<p class="HighlightsSeeReference">See 17 for PATIENT COUNSELING INFORMATION and FDA-approved patient labeling.</p>
<p class="HighlightsRevision">Revised: 2/2015</p>
</div></td></tr></table></div>
<div id="Index" class="Index"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1 class="Colspan">FULL PRESCRIBING INFORMATION: CONTENTS<a href="#footnote-content" name="footnote-reference-content">*</a>
</h1>
<h1><a href="#section-1" class="toc"></a></h1>
<h1><a href="#section-1" class="toc">1 INDICATIONS AND USAGE</a></h1>
<h2><a href="#section-1.2" class="toc">1.2 Prevention of Postmenopausal <span class="product-label-link" type="condition" conceptid="80502" conceptname="Osteoporosis">Osteoporosis</span></a></h2>
<h1><a href="#section-2" class="toc">2 DOSAGE AND ADMINISTRATION</a></h1>
<h2><a href="#section-2.1" class="toc">2.1 Treatment of Moderate to Severe Vasomotor Symptoms due to <span class="product-label-link" type="condition" conceptid="4059477" conceptname="Menopause">Menopause</span></a></h2>
<h2><a href="#section-2.2" class="toc">2.2 Prevention of Postmenopausal <span class="product-label-link" type="condition" conceptid="80502" conceptname="Osteoporosis">Osteoporosis</span></a></h2>
<h1><a href="#section-3" class="toc">3 DOSAGE FORMS AND STRENGTHS</a></h1>
<h1><a href="#section-4" class="toc">4 CONTRAINDICATIONS</a></h1>
<h1><a href="#section-5" class="toc">5 WARNINGS AND PRECAUTIONS</a></h1>
<h2><a href="#section-5.1" class="toc">5.1 <span class="product-label-link" type="condition" conceptid="134057" conceptname="Disorder of cardiovascular system">Cardiovascular Disorders</span></a></h2>
<h2><a href="#section-5.2" class="toc">5.2 Malignant Neoplasms</a></h2>
<h2><a href="#section-5.3" class="toc">5.3 Probable <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">Dementia</span></a></h2>
<h2><a href="#section-5.4" class="toc">5.4 <span class="product-label-link" type="condition" conceptid="192353" conceptname="Disorder of gallbladder">Gallbladder Disease</span></a></h2>
<h2><a href="#section-5.5" class="toc">5.5 <span class="product-label-link" type="condition" conceptid="435511" conceptname="Hypercalcemia">Hypercalcemia</span></a></h2>
<h2><a href="#section-5.6" class="toc">5.6 Visual Abnormalities</a></h2>
<h2><a href="#section-5.7" class="toc">5.7 Addition of a Progestin When a Woman Has Not Had a Hysterectomy</a></h2>
<h2><a href="#section-5.8" class="toc">5.8 Elevated Blood Pressure</a></h2>
<h2><a href="#section-5.9" class="toc">5.9 <span class="product-label-link" type="condition" conceptid="440360" conceptname="Pure hyperglyceridemia">Hypertriglyceridemia</span></a></h2>
<h2><a href="#section-5.10" class="toc">5.10 <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span> and/or a Past History of <span class="product-label-link" type="condition" conceptid="4185719" conceptname="Cholestatic jaundice syndrome">Cholestatic Jaundice</span></a></h2>
<h2><a href="#section-5.11" class="toc">5.11 <span class="product-label-link" type="condition" conceptid="140673" conceptname="Hypothyroidism">Hypothyroidism</span></a></h2>
<h2><a href="#section-5.12" class="toc">5.12 <span class="product-label-link" type="condition" conceptid="4125002" conceptname="Idiopathic fluid retention">Fluid Retention</span></a></h2>
<h2><a href="#section-5.13" class="toc">5.13 <span class="product-label-link" type="condition" conceptid="435510" conceptname="Hypocalcemia">Hypocalcemia</span></a></h2>
<h2><a href="#section-5.14" class="toc">5.14 Exacerbation of <span class="product-label-link" type="condition" conceptid="433527" conceptname="Endometriosis">Endometriosis</span></a></h2>
<h2><a href="#section-5.15" class="toc">5.15 <span class="product-label-link" type="condition" conceptid="4307793" conceptname="Hereditary angioedema">Hereditary Angioedema</span></a></h2>
<h2><a href="#section-5.16" class="toc">5.16 Exacerbation of Other Conditions</a></h2>
<h2><a href="#section-5.17" class="toc">5.17 Laboratory Tests</a></h2>
<h2><a href="#section-5.18" class="toc">5.18 Drug-Laboratory Test Interactions</a></h2>
<h1><a href="#section-6" class="toc">6 ADVERSE REACTIONS</a></h1>
<h2><a href="#section-6.1" class="toc">6.1 Clinical Trials Experience</a></h2>
<h2><a href="#section-6.2" class="toc">6.2 Postmarketing Experience</a></h2>
<h1><a href="#section-7" class="toc">7 DRUG INTERACTIONS</a></h1>
<h2><a href="#section-7.1" class="toc">7.1 Effect of Other Drugs on Combined Hormonal Products</a></h2>
<h2><a href="#section-7.2" class="toc">7.2 Effect of Combined Hormonal Products on Other Drugs</a></h2>
<h1><a href="#section-8" class="toc">8 USE IN SPECIFIC POPULATIONS</a></h1>
<h2><a href="#section-8.1" class="toc">8.1 Pregnancy</a></h2>
<h2><a href="#section-8.2" class="toc">8.3 Nursing Mothers</a></h2>
<h2><a href="#section-8.3" class="toc">8.4 Pediatric Use</a></h2>
<h2><a href="#section-8.4" class="toc">8.5 Geriatric Use</a></h2>
<h2><a href="#section-8.5" class="toc">8.6 <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></a></h2>
<h2><a href="#section-8.6" class="toc">8.7 <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span></a></h2>
<h1><a href="#section-9" class="toc">10 OVERDOSAGE</a></h1>
<h1><a href="#section-10" class="toc">11 DESCRIPTION</a></h1>
<h1><a href="#section-11" class="toc">12 CLINICAL PHARMACOLOGY</a></h1>
<h2><a href="#section-11.1" class="toc">12.1 Mechanism of Action</a></h2>
<h2><a href="#section-11.2" class="toc">12.2 Pharmacodynamics</a></h2>
<h2><a href="#section-11.3" class="toc">12.3 Pharmacokinetics</a></h2>
<h1><a href="#section-12" class="toc">13 NONCLINICAL TOXICOLOGY</a></h1>
<h2><a href="#section-12.1" class="toc">13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</a></h2>
<h1><a href="#section-13" class="toc">14 CLINICAL STUDIES</a></h1>
<h2><a href="#section-13.1" class="toc">14.1 Effects on Vasomotor Symptoms</a></h2>
<h2><a href="#section-13.2" class="toc">14.2 Effects on the Endometrium</a></h2>
<h2><a href="#section-13.3" class="toc">14.3 Effects on <span class="product-label-link" type="condition" conceptid="195876" conceptname="Hematometra">Uterine Bleeding</span> or Spotting</a></h2>
<h2><a href="#section-13.4" class="toc">14.4 Effect on Bone Mineral Density</a></h2>
<h2><a href="#section-13.5" class="toc">14.5 Women’s Health Initiative Studies</a></h2>
<h2><a href="#section-13.6" class="toc">14.6 Women’s Health Initiative Memory Study</a></h2>
<h1><a href="#section-14" class="toc">15 REFERENCES</a></h1>
<h1><a href="#section-15" class="toc">16 HOW SUPPLIED/STORAGE AND HANDLING</a></h1>
<h2><a href="#section-15.1" class="toc">16.1 How Supplied</a></h2>
<h2><a href="#section-15.2" class="toc">16.2 Storage and Handling</a></h2>
<h1><a href="#section-16" class="toc">17 PATIENT COUNSELING INFORMATION</a></h1>
<h2><a href="#section-16.1" class="toc">17.1 Abnormal <span class="product-label-link" type="condition" conceptid="4129155" conceptname="Vaginal bleeding">Vaginal Bleeding</span></a></h2>
<h2><a href="#section-16.2" class="toc">17.2 Possible Serious Adverse Reactions with Estrogen Plus Progestin Therapy</a></h2>
<h2><a href="#section-16.3" class="toc">17.3 Possible Less Serious but Common Adverse Reactions with Estrogen Plus Progestin Therapy</a></h2>
<h2><a href="#section-19.1" class="toc">Jinteli® (norethindrone acetate and ethinyl estradiol tablets USP) 1 mg/5 mcg Carton Text</a></h2>
<dl class="Footnote">
<dt><a href="#footnote-reference-content" name="footnote-content">*</a></dt>
<dd>Sections or subsections omitted from the full prescribing information are not listed.</dd>
</dl>
</div></td></tr></table></div>
<div class="Contents">
<h1>FULL PRESCRIBING INFORMATION</h1>
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Warning">
<a name="ID_88d5471d-1de2-487a-9c26-0b2d13550033"></a><a name="section-1"></a><p></p>
<h1></h1>
<p class="First"><span class="Bold">WARNING: <span class="product-label-link" type="condition" conceptid="134057" conceptname="Disorder of cardiovascular system">CARDIOVASCULAR DISORDERS</span>, BREAST CANCER, ENDOMETRIAL CANCER AND PROBABLE <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">DEMENTIA</span> </span></p>
<p><span class="Bold"><span class="Underline">Estrogen Plus Progestin Therapy <br></span></span></p>
<p><span class="Bold"><span class="product-label-link" type="condition" conceptid="134057" conceptname="Disorder of cardiovascular system">Cardiovascular Disorders</span> and Probable <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">Dementia</span></span></p>
<p><span class="Bold">Estrogen plus progestin therapy should not be used for the prevention of cardiovascular disease or <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">dementia</span> <span class="Italics">[see Warnings and Precautions (<a href="#ID_37d6c252-eb1b-49ec-b65d-5be3dfa48a29">5.1</a>, <a href="#ID_b6c93caa-3b1a-4955-93b6-2c1d7d79d3e1">5.3</a>), and Clinical Studies (<a href="#ID_5296d075-c832-4f39-b7c9-2082c7c60538">14.5</a>, <a href="#ID_6085a306-55d1-4c11-9aab-45c08a1b53fe">14.6</a>)]</span>. <br></span></p>
<p><span class="Bold">The Women’s Health Initiative (WHI) estrogen plus progestin substudy reported an increased risk of <span class="product-label-link" type="condition" conceptid="4042396" conceptname="Deep thrombophlebitis">deep vein thrombosis</span> (DVT), <span class="product-label-link" type="condition" conceptid="440417" conceptname="Pulmonary embolism">pulmonary embolism</span> (PE), <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span> and <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span> (MI) in postmenopausal women (50 to 79 years of age) during 5.6 years of treatment with daily oral conjugated estrogens (CE) [0.625 mg] combined with medroxyprogesterone acetate (MPA) [2.5 mg], relative to placebo <span class="Italics">[see Warnings and Precautions (<a href="#ID_37d6c252-eb1b-49ec-b65d-5be3dfa48a29">5.1</a>), and Clinical Studies (<a href="#ID_5296d075-c832-4f39-b7c9-2082c7c60538">14.5</a>)]</span>. <br></span></p>
<p><span class="Bold">The WHI Memory Study (WHIMS) estrogen plus progestin ancillary study of the WHI reported an increased risk of developing probable <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">dementia</span> in postmenopausal women 65 years of age or older during 4 years of treatment with daily CE (0.625 mg) combined with MPA (2.5 mg), relative to placebo. It is unknown whether this finding applies to younger postmenopausal women <span class="Italics">[see Warnings and Precautions (<a href="#ID_b6c93caa-3b1a-4955-93b6-2c1d7d79d3e1">5.3</a>), Use in Specific Populations (<a href="#ID_047b0de5-d7ac-4eb7-b76b-3d20764b0a03">8.5</a>), and Clinical Studies (<a href="#ID_6085a306-55d1-4c11-9aab-45c08a1b53fe">14.6</a>)]</span>. </span></p>
<p><span class="Bold"></span></p>
<p><span class="Bold">                                                                             Breast Cancer <br>The WHI estrogen plus progestin substudy also demonstrated an increased risk of invasive breast cancer <span class="Italics">[see Warnings and Precautions (<a href="#ID_08fd3295-48f2-4e90-b7ac-6b8a20dfa6fc">5.2</a>), and Clinical Studies (<a href="#ID_5296d075-c832-4f39-b7c9-2082c7c60538">14.5</a>)]</span>.<br></span></p>
<p><span class="Bold">In the absence of comparable data, these risks should be assumed to be similar for other doses of CE and MPA and other combinations and dosage forms of estrogens and progestins. <br></span></p>
<p><span class="Bold">Estrogens with or without progestins should be prescribed at the lowest effective doses and for the shortest duration consistent with treatment goals and risks for the individual woman. <br></span></p>
<p><span class="Bold"><span class="Underline">Estrogen-Alone Therapy </span></span></p>
<p><span class="Bold"></span></p>
<p><span class="Bold">                                                                      Endometrial Cancer <br>There is an increased risk of endometrial cancer in a woman with a uterus who uses unopposed estrogens. Adding a progestin to estrogen therapy has been shown to reduce the risk of <span class="product-label-link" type="condition" conceptid="200775" conceptname="Endometrial hyperplasia">endometrial hyperplasia</span>, which may be a precursor to endometrial cancer. Adequate diagnostic measures, including directed or random endometrial sampling when indicated, should be undertaken to rule out malignancy in postmenopausal women with undiagnosed persistent or recurring abnormal genital <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> <span class="Italics">[see Warnings and Precautions (<a href="#ID_08fd3295-48f2-4e90-b7ac-6b8a20dfa6fc">5.2</a>)]</span>.</span></p>
<dl>
<dt> </dt>
<dd><span class="Bold"></span></dd>
<dt> </dt>
<dd><span class="Bold">      <span class="product-label-link" type="condition" conceptid="134057" conceptname="Disorder of cardiovascular system">Cardiovascular Disorders</span> and Probable <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">Dementia</span> <br>Estrogen-alone therapy should not be used for the prevention of cardiovascular disease or <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">dementia</span> <span class="Italics">[see Warnings and Precautions (<a href="#ID_37d6c252-eb1b-49ec-b65d-5be3dfa48a29">5.1</a>, <a href="#ID_b6c93caa-3b1a-4955-93b6-2c1d7d79d3e1">5.3</a>), and Clinical Studies (<a href="#ID_5296d075-c832-4f39-b7c9-2082c7c60538">14.5</a>, <a href="#ID_6085a306-55d1-4c11-9aab-45c08a1b53fe">14.6</a>)]</span>. <br></span></dd>
</dl>
<p><span class="Bold">The WHI estrogen-alone substudy reported increased risks of <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span> and DVT in postmenopausal women (50 to 79 years of age) during 7.1 years of treatment with daily oral CE (0.625 mg)-alone, relative to placebo <span class="Italics">[see Warnings and Precautions (<a href="#ID_37d6c252-eb1b-49ec-b65d-5be3dfa48a29">5.1</a>), and Clinical Studies (<a href="#ID_5296d075-c832-4f39-b7c9-2082c7c60538">14.5</a>)]. <br></span></span></p>
<p><span class="Bold">The WHIMS estrogen-alone ancillary study of the WHI reported an increased risk of developing probable <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">dementia</span> in postmenopausal women 65 years of age or older during 5.2 years of treatment with daily CE (0.625 mg)-alone, relative to placebo. It is unknown whether this finding applies to younger postmenopausal women <span class="Italics">[see Warnings and Precautions (<a href="#ID_b6c93caa-3b1a-4955-93b6-2c1d7d79d3e1">5.3</a>), Use in Specific Populations (<a href="#ID_047b0de5-d7ac-4eb7-b76b-3d20764b0a03">8.5</a>), and Clinical Studies (<a href="#ID_6085a306-55d1-4c11-9aab-45c08a1b53fe">14.6</a>)].<br></span></span></p>
<p><span class="Bold">In the absence of comparable data, these risks should be assumed to be similar for other doses of CE and other dosage forms of estrogens. </span></p>
<p><span class="Bold">Estrogens with or without progestins should be prescribed at the lowest effective doses and for the shortest duration consistent with treatment goals and risks for the individual woman.</span></p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="ID_e863b16b-a26c-4eb8-b5b6-d159f87b876c"></a><a name="section-1"></a><p></p>
<h1>1 INDICATIONS AND USAGE</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_dfd16e8f-b7b7-431f-bafa-e6442320b188"></a><a name="section-1.1"></a><p></p>
<h2>1.1 Treatment of Moderate to Severe Vasomotor Symptoms due to <span class="product-label-link" type="condition" conceptid="4059477" conceptname="Menopause">Menopause</span></h2>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_7b0c4c37-83bf-422b-90a6-e2746645ba9a"></a><a name="section-1.2"></a><p></p>
<h2>1.2 Prevention of Postmenopausal <span class="product-label-link" type="condition" conceptid="80502" conceptname="Osteoporosis">Osteoporosis</span></h2>
<p class="First"><span class="Bold">Limitation of Use </span></p>
<p>When prescribing solely for the prevention of postmenopausal <span class="product-label-link" type="condition" conceptid="80502" conceptname="Osteoporosis">osteoporosis</span>, therapy should only be considered for women at significant risk of <span class="product-label-link" type="condition" conceptid="80502" conceptname="Osteoporosis">osteoporosis</span> and non-estrogen medication should be carefully considered.</p>
</div>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="ID_b62fa50d-39dd-45d0-a039-946ba614ea82"></a><a name="section-2"></a><p></p>
<h1>2 DOSAGE AND ADMINISTRATION</h1>
<p class="First">Use of estrogen-alone, or in combination with a progestin, should be with the lowest effective dose and for the shortest duration consistent with treatment goals and risks for the individual woman. Postmenopausal women should be re-evaluated periodically as clinically appropriate to determine if treatment is still necessary.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_204cd19a-bfea-4963-9f3d-c6978d48cfa7"></a><a name="section-2.1"></a><p></p>
<h2>2.1 Treatment of Moderate to Severe Vasomotor Symptoms due to <span class="product-label-link" type="condition" conceptid="4059477" conceptname="Menopause">Menopause</span></h2>
<p class="First">Jinteli<span class="Bold"><span class="Italics"></span></span>therapy consists of a single tablet to be taken orally once daily.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_eb02fa37-db59-4599-94dc-0b76df45bdf0"></a><a name="section-2.2"></a><p></p>
<h2>2.2 Prevention of Postmenopausal <span class="product-label-link" type="condition" conceptid="80502" conceptname="Osteoporosis">Osteoporosis</span></h2>
<p class="First">Jinteli therapy consists of a single tablet taken orally once daily.</p>
</div>
</div>
<div class="Section" data-sectionCode="43678-2">
<a name="ID_057c7afa-7fcc-4339-ae40-aa8b33f229da"></a><a name="section-3"></a><p></p>
<h1>3 DOSAGE FORMS AND STRENGTHS</h1>
<p class="First">Jinteli<span class="Bold"><span class="Italics"></span></span>is available as: </p>
<p>1 mg/5 mcg: Each white, round, flat-faced, beveled-edge, unscored tablet contains 1 mg norethindrone acetate and 5 mcg ethinyl estradiol; debossed with stylized <span class="Bold">b</span> on one side and 125 on the other side.</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="ID_a47e2a7b-c689-4deb-a20b-615691f468ac"></a><a name="section-4"></a><p></p>
<h1>4 CONTRAINDICATIONS</h1>
<p class="First">Jinteli<span class="Bold"><span class="Italics"></span></span>is contraindicated in women with any of the following conditions: </p>
<dl>
<dt>•</dt>
<dd>Undiagnosed abnormal genital <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> </dd>
<dt>•</dt>
<dd>Known, suspected, or history of breast cancer </dd>
<dt>•</dt>
<dd>Known or suspected estrogen-dependent neoplasia </dd>
<dt>•</dt>
<dd>Active DVT, PE or a history of these conditions </dd>
<dt>•</dt>
<dd>Active arterial thromboembolic disease (for example, <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span> and MI), or a history of these conditions </dd>
<dt>•</dt>
<dd>Known <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylactic reaction</span> or <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioedema</span> to Jinteli</dd>
<dt>•</dt>
<dd>Known liver impairment or disease </dd>
<dt>•</dt>
<dd>Known protein C, protein S, or antithrombin deficiency, or other known thrombophilic disorders </dd>
<dt>•</dt>
<dd>Known or suspected pregnancy </dd>
</dl>
</div>
<div class="Section" data-sectionCode="43685-7">
<a name="ID_a799f7ad-2e83-4a6e-9574-3d63f884afac"></a><a name="section-5"></a><p></p>
<h1>5 WARNINGS AND PRECAUTIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_37d6c252-eb1b-49ec-b65d-5be3dfa48a29"></a><a name="section-5.1"></a><p></p>
<h2>5.1 <span class="product-label-link" type="condition" conceptid="134057" conceptname="Disorder of cardiovascular system">Cardiovascular Disorders</span></h2>
<p class="First">An increased risk of PE, DVT, <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span>, and MI has been reported with estrogen plus progestin therapy. An increased risk of <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span> and DVT has been reported with estrogen-alone therapy. Should any of these occur or be suspected, estrogen with or without progestin therapy should be discontinued immediately. <br></p>
<p>Risk factors for arterial vascular disease (for example, <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>, <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> mellitus, tobacco use, <span class="product-label-link" type="condition" conceptid="437827" conceptname="Pure hypercholesterolemia">hypercholesterolemia</span>, and <span class="product-label-link" type="condition" conceptid="433736" conceptname="Obesity">obesity</span>) and/or <span class="product-label-link" type="condition" conceptid="318775" conceptname="Venous embolism">venous thromboembolism</span> (VTE) (for example, personal history or family history of VTE, <span class="product-label-link" type="condition" conceptid="433736" conceptname="Obesity">obesity</span>, and <span class="product-label-link" type="condition" conceptid="257628" conceptname="Systemic lupus erythematosus">systemic lupus erythematosus</span>) should be managed appropriately. <br></p>
<p><span class="Italics"><span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">Stroke</span> <br></span></p>
<p>In the WHI estrogen plus progestin substudy, a statistically significant increased risk of <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span> was reported in women 50 to 79 years of age receiving daily CE (0.625 mg) plus MPA (2.5 mg) compared to women in the same age group receiving placebo (33 versus 25 per 10,000 women-years) <span class="Italics">[see Clinical Studies (</span><span class="Italics"><a href="#ID_5296d075-c832-4f39-b7c9-2082c7c60538">14.5</a>)]</span>. The increase in risk was demonstrated after the first year and persisted.<span class="Sup">1 </span>Should a <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span> occur or be suspected, estrogen plus progestin therapy should be discontinued immediately. <br></p>
<p>In the WHI estrogen-alone substudy, a statistically significant increased risk of <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span> was reported in women 50 to 79 years of age receiving daily conjugated estrogens CE (0.625 mg)-alone compared to women in the same age group receiving placebo (45 versus 33 per 10,000 women-years). The increase in risk was demonstrated in year 1 and persisted <span class="Italics">[see Clinical Studies (</span><span class="Italics"><a href="#ID_5296d075-c832-4f39-b7c9-2082c7c60538">14.5</a>)]</span>. Should a <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span> occur or be suspected, estrogen-alone therapy should be discontinued immediately. <br></p>
<p>Subgroup analyses of women 50 to 59 years of age suggest no increased risk of <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span> for those women receiving CE (0.625 mg)-alone versus those receiving placebo (18 versus 21 per 10,000 women-years).<span class="Sup">1 </span><br></p>
<p><span class="Italics">Coronary Heart Disease <br></span></p>
<p>In the WHI estrogen plus progestin substudy, there was a statistically non-significant increased risk of coronary heart disease (CHD) events (defined as nonfatal MI, silent MI, or CHD <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>) reported in women receiving daily CE (0.625 mg) plus MPA (2.5 mg) compared to women receiving placebo (41 versus 34 per 10,000 women-years).<span class="Sup">1 </span>An increase in relative risk was demonstrated in year 1, and a trend toward decreasing relative risk was reported in years 2 through 5 <span class="Italics">[see Clinical Studies (</span><span class="Italics"><a href="#ID_5296d075-c832-4f39-b7c9-2082c7c60538">14.5</a>)].</span><br></p>
<p>In the WHI estrogen-alone substudy, no overall effect on CHD events was reported in women receiving estrogen-alone compared to placebo<span class="Sup">2 </span><span class="Italics">[see Clinical Studies (</span><span class="Italics"><a href="#ID_5296d075-c832-4f39-b7c9-2082c7c60538">14.5</a>)]. <br></span></p>
<p>Subgroup analyses of women 50 to 59 years of age suggest a statistically non-significant reduction in CHD events (CE [0.625 mg]-alone compared to placebo) in women with less than 10 years since <span class="product-label-link" type="condition" conceptid="4059477" conceptname="Menopause">menopause</span> (8 versus 16 per 10,000 woman-years).<span class="Sup">1 </span><br></p>
<p>In postmenopausal women with documented heart disease (n = 2,763), average 66.7 years of age, in a controlled clinical trial of secondary prevention of cardiovascular disease (Heart and Estrogen/Progestin Replacement Study [HERS]), treatment with daily CE (0.625 mg) plus MPA (2.5 mg) demonstrated no cardiovascular benefit. During an average follow-up of 4.1 years, treatment with CE plus MPA did not reduce the overall rate of CHD events in postmenopausal women with established CHD. There were more CHD events in the CE plus MPA-treated group than in the placebo group in year 1, but not during the subsequent years. Two thousand, three hundred and twenty one (2,321) women from the original HERS trial agreed to participate in an open label extension of HERS, HERS II. Average follow-up in HERS II was an additional 2.7 years, for a total of 6.8 years overall. Rates of CHD events were comparable among women in the CE plus MPA group and the placebo group in HERS, HERS II, and overall. <br></p>
<p><span class="Italics"><span class="product-label-link" type="condition" conceptid="318775" conceptname="Venous embolism">Venous Thromboembolism</span> <br></span></p>
<p>In the WHI estrogen plus progestin substudy, a statistically significant 2 fold greater rate of VTE (DVT and PE) was reported in women receiving daily CE (0.625 mg) plus MPA (2.5 mg) compared to women receiving placebo (35 versus 17 per 10,000 women-years). Statistically significant increases in risk for both DVT (26 versus 13 per 10,000 women-years) and PE (18 versus 8 per 10,000 women-years) were also demonstrated. The increase in VTE risk was demonstrated during the first year and persisted<span class="Sup">3 </span>[see Clinical Studies (<span class="Italics"><a href="#ID_5296d075-c832-4f39-b7c9-2082c7c60538">14.5</a>)]</span>. Should a VTE occur or be suspected, estrogen plus progestin therapy should be discontinued immediately.</p>
<p></p>
<p>In the WHI estrogen-alone substudy, the risk of VTE was increased for women receiving daily CE (0.625 mg)-alone compared to placebo (30 versus 22 per 10,000 women-years), although only the increased risk of DVT reached statistical significance (23 versus 15 per 10,000 women-years). The increase in VTE risk was demonstrated during the first 2 years<span class="Sup">4 </span><span class="Italics">[see Clinical Studies (</span><span class="Italics"><a href="#ID_5296d075-c832-4f39-b7c9-2082c7c60538">14.5</a>)]</span>. Should a VTE occur or be suspected, estrogen-alone therapy should be discontinued immediately. <br></p>
<p>If feasible, estrogens should be discontinued at least 4 to 6 weeks before surgery of the type associated with an increased risk of <span class="product-label-link" type="condition" conceptid="4159647" conceptname="Thromboembolic disorder">thromboembolism</span> or during periods of prolonged immobilization.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_08fd3295-48f2-4e90-b7ac-6b8a20dfa6fc"></a><a name="section-5.2"></a><p></p>
<h2>5.2 Malignant Neoplasms</h2>
<p class="First"><span class="Italics">Breast Cancer<br></span></p>
<p>The most important randomized clinical trial providing information about breast cancer in estrogen plus progestin users is the WHI substudy of daily CE (0.625 mg) plus MPA (2.5 mg). After a mean follow-up of 5.6 years, the estrogen plus progestin substudy reported an increased risk of invasive breast cancer in women who took daily CE plus MPA. In this substudy, prior use of estrogen-alone or estrogen plus progestin therapy was reported by 26 percent of the women. The relative risk of invasive breast cancer was 1.24, and the absolute risk was 41 versus 33 cases per 10,000 women-years for CE plus MPA compared with placebo <span class="Italics">[see Clinical Studies (</span><span class="Italics"><a href="#ID_5296d075-c832-4f39-b7c9-2082c7c60538">14.5</a>)]</span>. Among women who reported prior use of hormone therapy, the relative risk of invasive breast cancer was 1.86 and the absolute risk was 46 versus 25 cases per 10,000 women-years for CE plus MPA compared with placebo. Among women who reported no prior use of hormone therapy, the relative risk of invasive breast cancer was 1.09, and the absolute risk was 40 versus 36 cases per 10,000 women-years for CE plus MPA compared with placebo. In the same substudy, invasive breast cancers were larger, were more likely to be node positive, and were diagnosed at a more advanced stage in the CE (0.625 mg) plus MPA (2.5 mg) group compared with the placebo group. <span class="product-label-link" type="condition" conceptid="4116496" conceptname="Disseminated adenocarcinoma">Metastatic disease</span> was rare with no apparent difference between the two groups. Other prognostic factors, such as histologic subtype, grade and hormone receptor status did not differ between the groups<span class="Sup">5 </span><span class="Italics">[see Clinical Studies (</span><span class="Italics"><a href="#ID_5296d075-c832-4f39-b7c9-2082c7c60538">14.5</a>)]</span>. <br></p>
<p>The most important randomized clinical trial providing information about breast cancer in estrogen-alone users is the WHI substudy of daily CE (0.625 mg)-alone. In the WHI estrogen-alone substudy, after an average follow up of 7.1 years, daily CE-alone was not associated with an increased risk of invasive breast cancer (relative risk [RR] 0.8 <span class="Italics">[see Clinical Studies (</span><span class="Italics"><a href="#ID_5296d075-c832-4f39-b7c9-2082c7c60538">14.5</a>)]</span>. <br></p>
<p>Consistent with the WHI clinical trials, observational studies have also reported an increased risk of breast cancer for estrogen plus progestin therapy, and a smaller increased risk for estrogen-alone therapy, after several years of use. The risk increased with duration of use, and appeared to return to baseline over about 5 years after stopping treatment (only the observational studies have substantial data on risk after stopping). Observational studies also suggest that the risk of breast cancer was greater, and became apparent earlier, with estrogen plus progestin therapy as compared to estrogen-alone therapy. However, these studies have not found significant variation in the risk of breast cancer among different estrogen plus progestin combinations, doses, or routes of administration. <br></p>
<p>The use of estrogen-alone and estrogen plus progestin has been reported to result in an increase in abnormal mammograms requiring further evaluation. <br></p>
<p>All women should receive yearly breast examinations by a healthcare provider and perform monthly breast self-examinations. In addition, mammography examinations should be scheduled based on patient age, risk factors and prior mammogram results.<span class="Italics"><br></span></p>
<p><span class="Italics">Endometrial Cancer <br></span></p>
<p><span class="product-label-link" type="condition" conceptid="200775" conceptname="Endometrial hyperplasia">Endometrial hyperplasia</span> (a possible precursor of endometrial cancer) has been reported to occur at a rate of approximately 1 percent or less with Jinteli. <br></p>
<p>An increased risk of endometrial cancer has been reported with the use of unopposed estrogen therapy in a woman with a uterus. The reported endometrial cancer risk among unopposed estrogen users is about 2 to 12 times greater than in non-users, and appears dependent on duration of treatment and on estrogen dose. Most studies show no significant increased risk associated with use of estrogens for less than 1 year. The greatest risk appears associated with prolonged use, with increased risks of 15 to 24 fold for 5 to 10 years or more. This risk has been shown to persist for at least 8 to 15 years after estrogen therapy is discontinued.</p>
<p></p>
<p>Clinical surveillance of all women using estrogen-alone or estrogen plus progestin therapy is important. Adequate diagnostic measures, including directed or random endometrial sampling when indicated, should be undertaken to rule out malignancy in postmenopausal women with undiagnosed persistent or recurring abnormal genital <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>. </p>
<p><br>There is no evidence that the use of natural estrogens results in a different endometrial risk profile than synthetic estrogens of equivalent estrogen dose. Adding a progestin to estrogen therapy in postmenopausal women has been shown to reduce the risk of <span class="product-label-link" type="condition" conceptid="200775" conceptname="Endometrial hyperplasia">endometrial hyperplasia</span>, which may be a precursor to endometrial cancer. <br></p>
<p><span class="Italics">Ovarian Cancer <br></span></p>
<p>The WHI estrogen plus progestin substudy reported a statistically non-significant increased risk of ovarian cancer. After an average follow-up of 5.6 years, the relative risk for ovarian cancer for CE plus MPA versus placebo was 1.58 (95 percent CI, 0.77 to 3.24). The absolute risk for CE plus MPA versus placebo was 4 versus 3 cases per 10,000 women-years.<span class="Sup">7 </span>In some epidemiologic studies, the use of estrogen plus progestin and estrogen-only products, in particular for 5 or more years, has been associated with an increased risk of ovarian cancer. However, the duration of exposure associated with increased risk is not consistent across all epidemiologic studies and some report no association.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_b6c93caa-3b1a-4955-93b6-2c1d7d79d3e1"></a><a name="section-5.3"></a><p></p>
<h2>5.3 Probable <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">Dementia</span></h2>
<p class="First">In the WHIMS estrogen plus progestin ancillary study of WHI, a population of 4,532 postmenopausal women 65 to 79 years of age was randomized to daily CE (0.625 mg) plus MPA (2.5 mg) or placebo.<br></p>
<p>After an average follow-up of 4 years, 40 women in the CE plus MPA group and 21 women in the placebo group were diagnosed with probable <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">dementia</span>. The relative risk of probable <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">dementia</span> for CE plus MPA versus placebo was 2.05 (95 percent CI, 1.21 to 3.48). The absolute risk of probable <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">dementia</span> for CE plus MPA versus placebo was 45 versus 22 cases per 10,000 women-years<span class="Sup">8 </span><span class="Italics">[see Use in Specific Populations (</span><span class="Italics"><a href="#ID_047b0de5-d7ac-4eb7-b76b-3d20764b0a03">8.5</a>), and Clinical Studies (<a href="#ID_6085a306-55d1-4c11-9aab-45c08a1b53fe">14.6</a>)]</span>. <br></p>
<p>In the WHIMS estrogen-alone ancillary study of WHI, a population of 2,947 hysterectomized women 65 to 79 years of age was randomized to daily CE (0.625 mg)-alone or placebo. <br></p>
<p>After an average follow-up of 5.2 years, 28 women in the estrogen-alone group and 19 women in the placebo group were diagnosed with probable <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">dementia</span>. The relative risk of probable <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">dementia</span> for CE-alone versus placebo was 1.49 (95 percent CI, 0.83 to 2.66). The absolute risk of probable <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">dementia</span> for CE-alone versus placebo was 37 versus 25 cases per 10,000 women-years<span class="Sup">8 </span><span class="Italics">[see Use in Specific Populations (</span><span class="Italics"><a href="#ID_047b0de5-d7ac-4eb7-b76b-3d20764b0a03">8.5</a>), and Clinical Studies (<a href="#ID_6085a306-55d1-4c11-9aab-45c08a1b53fe">14.6</a>)]. <br></span></p>
<p>When data from the two populations in the WHIMS estrogen-alone and estrogen plus progestin ancillary studies were pooled as planned in the WHIMS protocol, the reported overall relative risk for probable <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">dementia</span> was </p>
<p>1.76 (95 percent CI, 1.19 to 2.6). Since both ancillary substudies were conducted in women 65 to 79 years of age, it is unknown whether these findings apply to younger postmenopausal women<span class="Sup">8 </span><span class="Italics">[see Use in Specific Populations (</span><span class="Italics"><a href="#ID_047b0de5-d7ac-4eb7-b76b-3d20764b0a03">8.5</a>), and Clinical Studies (<a href="#ID_6085a306-55d1-4c11-9aab-45c08a1b53fe">14.6</a>)]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_6a327e5a-d4ae-475a-a1cd-2f781f95a52e"></a><a name="section-5.4"></a><p></p>
<h2>5.4 <span class="product-label-link" type="condition" conceptid="192353" conceptname="Disorder of gallbladder">Gallbladder Disease</span></h2>
<p class="First">A 2 to 4 fold increase in the risk of <span class="product-label-link" type="condition" conceptid="192353" conceptname="Disorder of gallbladder">gallbladder disease</span> requiring surgery in postmenopausal women receiving estrogens has been reported.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_5c282fda-1f30-4808-9fbb-a36514600815"></a><a name="section-5.5"></a><p></p>
<h2>5.5 <span class="product-label-link" type="condition" conceptid="435511" conceptname="Hypercalcemia">Hypercalcemia</span></h2>
<p class="First">Estrogen administration may lead to severe <span class="product-label-link" type="condition" conceptid="435511" conceptname="Hypercalcemia">hypercalcemia</span> in women with breast cancer and bone <span class="product-label-link" type="condition" conceptid="432851" conceptname="Secondary malignant neoplastic disease">metastases</span>. If <span class="product-label-link" type="condition" conceptid="435511" conceptname="Hypercalcemia">hypercalcemia</span> occurs, use of the drug should be stopped and appropriate measures taken to reduce the serum calcium level.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_416fdc25-421d-464d-8381-a6bfcf83f19b"></a><a name="section-5.6"></a><p></p>
<h2>5.6 Visual Abnormalities</h2>
<p class="First">Retinal vascular <span class="product-label-link" type="condition" conceptid="4130722" conceptname="Thrombosis">thrombosis</span> has been reported in women receiving estrogens. Discontinue medication pending examination if there is sudden partial or complete <span class="product-label-link" type="condition" conceptid="377551" conceptname="Blind hypertensive eye">loss of vision</span>, or a sudden onset of <span class="product-label-link" type="condition" conceptid="436700" conceptname="Exophthalmos">proptosis</span>, <span class="product-label-link" type="condition" conceptid="373474" conceptname="Diplopia">diplopia</span>, or <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine</span>. If examination reveals <span class="product-label-link" type="condition" conceptid="4308632" conceptname="Optic disc edema">papilledema</span> or retinal vascular lesions, estrogens should be permanently discontinued.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_56b989fe-9c8b-4418-99b3-9c46eede4fbf"></a><a name="section-5.7"></a><p></p>
<h2>5.7 Addition of a Progestin When a Woman Has Not Had a Hysterectomy</h2>
<p class="First">Studies of the addition of a progestin for 10 or more days of a cycle of estrogen administration or daily with estrogen in a continuous regimen, have reported a lowered incidence of <span class="product-label-link" type="condition" conceptid="200775" conceptname="Endometrial hyperplasia">endometrial hyperplasia</span> than would be induced by estrogen treatment alone. <span class="product-label-link" type="condition" conceptid="200775" conceptname="Endometrial hyperplasia">Endometrial hyperplasia</span> may be a precursor to endometrial cancer. <br></p>
<p>There are, however, possible risks that may be associated with the use of progestins with estrogens compared to estrogen-alone regimens. These include an increased risk of breast cancer.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_f7e9ee6e-51b5-4012-9279-e0d95fc51ac3"></a><a name="section-5.8"></a><p></p>
<h2>5.8 Elevated Blood Pressure</h2>
<p class="First">In a small number of case reports, substantial increases in blood pressure have been attributed to idiosyncratic reactions to estrogens. In a large, randomized, placebo-controlled clinical trial, a generalized effect of estrogen therapy on blood pressure was not seen.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_8f8118b7-8533-4f57-9940-4f0424dead4c"></a><a name="section-5.9"></a><p></p>
<h2>5.9 <span class="product-label-link" type="condition" conceptid="440360" conceptname="Pure hyperglyceridemia">Hypertriglyceridemia</span></h2>
<p class="First">In women with pre-existing <span class="product-label-link" type="condition" conceptid="440360" conceptname="Pure hyperglyceridemia">hypertriglyceridemia</span>, estrogen therapy may be associated with elevations of plasma triglycerides leading to <span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">pancreatitis</span>. Consider discontinuation of treatment if <span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">pancreatitis</span> occurs.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_ae25c714-c08c-4900-99c9-c2613eac6bd7"></a><a name="section-5.10"></a><p></p>
<h2>5.10 <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span> and/or a Past History of <span class="product-label-link" type="condition" conceptid="4185719" conceptname="Cholestatic jaundice syndrome">Cholestatic Jaundice</span></h2>
<p class="First">Estrogens may be poorly metabolized in women with <span class="product-label-link" type="condition" conceptid="4326594" conceptname="Abnormal liver function">impaired liver function</span>. For women with a history of <span class="product-label-link" type="condition" conceptid="4185719" conceptname="Cholestatic jaundice syndrome">cholestatic jaundice</span> associated with past estrogen use or with pregnancy, caution should be exercised and in the case of recurrence, medication should be discontinued.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_a820852e-e18a-455c-94ca-175660fac50e"></a><a name="section-5.11"></a><p></p>
<h2>5.11 <span class="product-label-link" type="condition" conceptid="140673" conceptname="Hypothyroidism">Hypothyroidism</span></h2>
<p class="First">Estrogen administration leads to increased thyroid-binding globulin (TBG) levels. Women with <span class="product-label-link" type="condition" conceptid="4193309" conceptname="Thyroid function tests normal">normal thyroid function</span> can compensate for the increased TBG by making more thyroid hormone, thus maintaining free T<span class="Sub">4</span> and T<span class="Sub">3</span> serum concentrations in the normal range. Women dependent on thyroid hormone replacement therapy who are also receiving estrogen may require increased doses of their thyroid replacement therapy. These women should have their thyroid function monitored in order to maintain their free thyroid hormone levels in an acceptable range.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_afea8a05-a5d6-44c6-8696-214aa279a76f"></a><a name="section-5.12"></a><p></p>
<h2>5.12 <span class="product-label-link" type="condition" conceptid="4125002" conceptname="Idiopathic fluid retention">Fluid Retention</span></h2>
<p class="First">Estrogens plus progestins may cause some degree of <span class="product-label-link" type="condition" conceptid="4125002" conceptname="Idiopathic fluid retention">fluid retention</span>. Women with conditions that might be influenced by this factor, such as cardiac or <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>, warrant careful observation when estrogens plus progestins are prescribed.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_2820bd49-b5e6-4a01-ab1b-547bdd959d65"></a><a name="section-5.13"></a><p></p>
<h2>5.13 <span class="product-label-link" type="condition" conceptid="435510" conceptname="Hypocalcemia">Hypocalcemia</span></h2>
<p class="First">Estrogen therapy should be used with caution in women with <span class="product-label-link" type="condition" conceptid="140362" conceptname="Hypoparathyroidism">hypoparathyroidism</span> as estrogen-induced <span class="product-label-link" type="condition" conceptid="435510" conceptname="Hypocalcemia">hypocalcemia</span> may occur.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_cc7155db-1356-46f7-a041-1ffeeaae5376"></a><a name="section-5.14"></a><p></p>
<h2>5.14 Exacerbation of <span class="product-label-link" type="condition" conceptid="433527" conceptname="Endometriosis">Endometriosis</span></h2>
<p class="First">A few cases of malignant transformation of residual endometrial implants have been reported in women treated post-hysterectomy with estrogen-alone therapy. For women known to have residual <span class="product-label-link" type="condition" conceptid="433527" conceptname="Endometriosis">endometriosis</span> post-hysterectomy, the addition of progestin should be considered.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_1ea76bb3-9e99-48bc-a165-6ae1c544e3e4"></a><a name="section-5.15"></a><p></p>
<h2>5.15 <span class="product-label-link" type="condition" conceptid="4307793" conceptname="Hereditary angioedema">Hereditary Angioedema</span></h2>
<p class="First">Exogenous estrogens may exacerbate symptoms of <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioedema</span> in women with <span class="product-label-link" type="condition" conceptid="4307793" conceptname="Hereditary angioedema">hereditary angioedema</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_6fb428a4-2ae0-45ec-8c9b-32118c384d78"></a><a name="section-5.16"></a><p></p>
<h2>5.16 Exacerbation of Other Conditions</h2>
<p class="First">Estrogen therapy may cause an <span class="product-label-link" type="condition" conceptid="257581" conceptname="Exacerbation of asthma">exacerbation of asthma</span>, <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> mellitus, <span class="product-label-link" type="condition" conceptid="380378" conceptname="Epilepsy">epilepsy</span>, <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine</span>, <span class="product-label-link" type="condition" conceptid="4305376" conceptname="Porphyria">porphyria</span>, <span class="product-label-link" type="condition" conceptid="257628" conceptname="Systemic lupus erythematosus">systemic lupus erythematosus</span> and hepatic <span class="product-label-link" type="condition" conceptid="441818" conceptname="Hemangioma">hemangiomas</span>, and should be used with caution in women with these conditions.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_b6117575-3186-459e-b46e-f94eeae7d918"></a><a name="section-5.17"></a><p></p>
<h2>5.17 Laboratory Tests</h2>
<p class="First">Serum follicle stimulating hormone (FSH) and estradiol levels have not been shown to be useful in the management of moderate to severe vasomotor symptoms.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_d3e1ee6a-160c-4179-976f-b432492c4148"></a><a name="section-5.18"></a><p></p>
<h2>5.18 Drug-Laboratory Test Interactions</h2>
<p class="First">Accelerated <span class="product-label-link" type="condition" conceptid="4173906" conceptname="Clotting factor II assay">prothrombin</span> time, partial thromboplastin time, and platelet aggregation time; increased platelet count; increased factors II, VII antigen, VIII antigen, VIII coagulant activity, IX, X, XII, VII-X complex, IIVII-X complex, and beta-thromboglobulin; decreased levels of antifactor Xa and antithrombin III, decreased antithrombin III activity; increased levels of fibrinogen and fibrinogen activity; increased <span class="product-label-link" type="condition" conceptid="4238994" conceptname="Plasminogen assay">plasminogen</span> antigen and activity. <br></p>
<p>Increased TBG levels leading to increased circulating total thyroid hormone levels as measured by protein-bound iodine (PBI), T<span class="Sub">4</span> levels (by column or by radioimmunoassay) or T<span class="Sub">3</span> levels by radioimmunoassay. T<span class="Sub">3</span> resin uptake is decreased, reflecting the elevated TBG. Free T<span class="Sub">4</span> and free T<span class="Sub">3</span> concentrations are unaltered. Women on thyroid replacement therapy may require higher doses of thyroid hormone.</p>
<p></p>
<p>Other binding proteins may be elevated in serum, for example, corticosteroid binding globulin (CBG), sex hormone-binding globulin (SHBG), leading to increased total circulating corticosteroids and sex steroids, respectively. Jinteli<span class="Bold"><span class="Italics"></span></span>1/5 was associated with an SHBG increase of 22 percent. Free hormone concentrations, such as testosterone and estradiol, may be decreased. Other plasma proteins may be increased (angiotensinogen/renin substrate, alpha-1-antitrypsin, <span class="product-label-link" type="condition" conceptid="4294533" conceptname="Ferroxidase">ceruloplasmin</span>). <br></p>
<p>Increased plasma high-density lipoprotein (HDL) and HDL<span class="Sub">2</span> <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span> subfraction concentrations, reduced low-density lipoprotein (LDL) <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span> concentration, increased triglycerides levels. <br></p>
<p>Impaired glucose tolerance.</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="ID_d05f1b5f-fe96-4c4b-9c5e-5ec24f961395"></a><a name="section-6"></a><p></p>
<h1>6 ADVERSE REACTIONS</h1>
<p class="First">The following serious adverse reactions are discussed elsewhere in the labeling: </p>
<dl>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="134057" conceptname="Disorder of cardiovascular system">Cardiovascular Disorders</span> <span class="Italics">[see Boxed Warning, Warnings and Precautions (<a href="#ID_37d6c252-eb1b-49ec-b65d-5be3dfa48a29">5.1</a>)]</span>. </dd>
<dt>•</dt>
<dd>Malignant Neoplasms <span class="Italics">[see Boxed Warning, Warnings and Precautions (<a href="#ID_08fd3295-48f2-4e90-b7ac-6b8a20dfa6fc">5.2</a>)]</span>. </dd>
</dl>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_0a4464a2-1af2-464e-bb8e-1e37f12a6406"></a><a name="section-6.1"></a><p></p>
<h2>6.1 Clinical Trials Experience</h2>
<p class="First">Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.<br></p>
<p>Adverse reactions reported by ≥ 5 percent of subjects in controlled clinical studies of Jinteli are shown in <a href="#Table_1">Table 1</a>.</p>
<table width="100%">
<col width="28%">
<col width="23%">
<col width="25%">
<col width="23%">
<tfoot><tr><td colspan="4" align="left"><dl class="Footnote">
<dt><a name="footnote-1" href="#footnote-reference-1">*</a></dt>
<dd>The total number of subjects for each body system may be less than the number of subjects with AEs in that body system because a subject may have had more than one AE per body system</dd>
</dl></td></tr></tfoot>
<tbody class="Headless">
<tr class="First"><td class="Botrule Toprule" align="center" colspan="4"><p class="First"><span class="Bold">Table 1.  Associated Adverse Reactions Reported by ≥ 5 Percent of Subjects by Body System</span><a name="footnote-reference-1" href="#footnote-1" class="Sup">*</a></p></td></tr>
<tr>
<td class="Botrule" rowspan="2"><p class="First">BODY SYSTEM/   Adverse Reaction</p></td>
<td class="Botrule Toprule" align="center" colspan="3"><p class="First">Number (Percent) of Subjects</p></td>
</tr>
<tr>
<td class="Botrule Toprule" align="center">
<p class="First">Placebo </p>
<p>N = 247</p>
</td>
<td class="Botrule Toprule" align="center">
<p class="First">Jinteli 0.5/2.5 </p>
<p>N = 244</p>
</td>
<td class="Botrule Toprule" align="center">
<p class="First">Jinteli 1/5 </p>
<p>N = 258</p>
</td>
</tr>
<tr>
<td class="Toprule">
<p class="First">BODY AS A WHOLE</p>
<p>         <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">Edema</span> – Generalized</p>
<p>         <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span></p>
</td>
<td class="Toprule" align="center">
<p class="First">23 (12.8)</p>
<p>10 (4)</p>
<p>12 (4.9)</p>
</td>
<td class="Toprule" align="center">
<p class="First">30 (16.9)</p>
<p>12 (4.9)</p>
<p>14 (5.7)</p>
</td>
<td class="Toprule" align="center">
<p class="First">30 (15.7)</p>
<p>11 (43)</p>
<p>16 (6.2)</p>
</td>
</tr>
<tr>
<td>
<p class="First">DIGESTIVE SYSTEM</p>
<p>         <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">Abdominal Pain</span></p>
</td>
<td align="center">
<p class="First">8 (4.4)</p>
<p>3 (1.2)</p>
</td>
<td align="center">
<p class="First">17 (9.6)</p>
<p>13 (5.3)</p>
</td>
<td align="center">
<p class="First">25 (13.1)</p>
<p>14 (6.8)</p>
</td>
</tr>
<tr>
<td class="Botrule">
<p class="First">UROGENITAL SYSTEM</p>
<p>          <span class="product-label-link" type="condition" conceptid="73819" conceptname="Pain of breast">Breast Pain</span></p>
</td>
<td class="Botrule" align="center">
<p class="First">20 (11.1)</p>
<p>9 (3.6)</p>
</td>
<td class="Botrule" align="center">
<p class="First">34 (19.2)</p>
<p>22 (9)</p>
</td>
<td class="Botrule" align="center">
<p class="First">45 (23.6)</p>
<p>20 (7.8)</p>
</td>
</tr>
<tr class="Last"><td class="Toprule" colspan="4"></td></tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_49c48beb-a98f-4d65-97d2-4927f9319ecf"></a><a name="section-6.2"></a><p></p>
<h2>6.2 Postmarketing Experience</h2>
<p class="First">The following additional adverse reactions have been identified during post-approval use of Jinteli. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure. <br></p>
<p><span class="Italics">Genitourinary System <br></span></p>
<p>Changes in <span class="product-label-link" type="condition" conceptid="4129155" conceptname="Vaginal bleeding">vaginal bleeding</span> pattern and abnormal <span class="product-label-link" type="condition" conceptid="4161407" conceptname="Withdrawal bleeding">withdrawal bleeding</span> or flow; breakthrough <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>; spotting; increase in size of uterine leiomyomata, <span class="product-label-link" type="condition" conceptid="4081648" conceptname="Acute vaginitis">vaginitis</span>, including <span class="product-label-link" type="condition" conceptid="198363" conceptname="Candidiasis of vagina">vaginal candidiasis</span>; change in amount of cervical secretion; changes in cervical <span class="product-label-link" type="condition" conceptid="376132" conceptname="Ectropion">ectropion</span>; ovarian cancer; <span class="product-label-link" type="condition" conceptid="200775" conceptname="Endometrial hyperplasia">endometrial hyperplasia</span>; endometrial cancer; uterine cancer; <span class="product-label-link" type="condition" conceptid="4129155" conceptname="Vaginal bleeding">vaginal hemorrhage</span>; <span class="product-label-link" type="condition" conceptid="193530" conceptname="Follicular cyst of ovary">ovarian cyst</span>; <span class="product-label-link" type="condition" conceptid="196168" conceptname="Irregular periods">irregular menstruation</span>; <span class="product-label-link" type="condition" conceptid="195012" conceptname="Intermenstrual bleeding - irregular">metrorrhagia</span>; <span class="product-label-link" type="condition" conceptid="4302555" conceptname="Menorrhagia">menorrhagia</span>; <span class="product-label-link" type="condition" conceptid="194696" conceptname="Dysmenorrhea">dysmenorrhea</span>; <span class="product-label-link" type="condition" conceptid="196473" conceptname="Hypertrophy of uterus">uterine enlargement</span>.</p>
<p></p>
<p><span class="Italics">Breasts <br></span></p>
<p><span class="product-label-link" type="condition" conceptid="4082445" conceptname="Tenderness">Tenderness</span>, enlargement, <span class="product-label-link" type="condition" conceptid="73819" conceptname="Pain of breast">breast pain</span>, <span class="product-label-link" type="condition" conceptid="4021485" conceptname="Nipple tenderness">nipple pain</span>, <span class="product-label-link" type="condition" conceptid="4181744" conceptname="Discharge from nipple">nipple discharge</span>, <span class="product-label-link" type="condition" conceptid="79884" conceptname="Galactorrhea not associated with childbirth">galactorrhea</span>; <span class="product-label-link" type="condition" conceptid="78804" conceptname="Fibrocystic disease of breast">fibrocystic breast</span> changes; breast cancer; <span class="product-label-link" type="condition" conceptid="77030" conceptname="Disorder of breast">breast disorder</span>; <span class="product-label-link" type="condition" conceptid="80767" conceptname="Breast lump">breast mass</span>; <span class="product-label-link" type="condition" conceptid="78474" conceptname="Hypertrophy of breast">breast enlargement</span>. <br></p>
<p><span class="Italics">Cardiovascular <br></span></p>
<p>Deep and superficial <span class="product-label-link" type="condition" conceptid="444247" conceptname="Venous thrombosis">venous thrombosis</span>; <span class="product-label-link" type="condition" conceptid="440417" conceptname="Pulmonary embolism">pulmonary embolism</span>; <span class="product-label-link" type="condition" conceptid="320741" conceptname="Thrombophlebitis">thrombophlebitis</span>; <span class="product-label-link" type="condition" conceptid="4130722" conceptname="Thrombosis">thrombosis</span>; <span class="product-label-link" type="condition" conceptid="77670" conceptname="Chest pain">chest pain</span>; <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span>; <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">cerebrovascular accident</span> (<span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span>); transient ischemic attack; <span class="product-label-link" type="condition" conceptid="4065756" conceptname="Hemiparesis">hemiparesis</span>; increase in blood pressure; irregular heart rate; <span class="product-label-link" type="condition" conceptid="315078" conceptname="Palpitations">palpitations</span>; <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">dyspnea</span>. <br></p>
<p><span class="Italics">Gastrointestinal <br></span></p>
<p><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>; <span class="product-label-link" type="condition" conceptid="4185719" conceptname="Cholestatic jaundice syndrome">cholestatic jaundice</span>; <span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">pancreatitis</span>, enlargement of hepatic <span class="product-label-link" type="condition" conceptid="441818" conceptname="Hemangioma">hemangiomas</span>; <span class="product-label-link" type="condition" conceptid="442597" conceptname="Swollen abdomen">bloating</span>, <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal cramps</span>; <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span>; increased incidence of <span class="product-label-link" type="condition" conceptid="192353" conceptname="Disorder of gallbladder">gallbladder disease</span>; <span class="product-label-link" type="condition" conceptid="192956" conceptname="Cholecystitis">cholecystitis</span>; <span class="product-label-link" type="condition" conceptid="4098112" conceptname="Biliary sludge">cholelithiasis</span>.</p>
<p></p>
<p><span class="Italics">Skin<br></span></p>
<p><span class="product-label-link" type="condition" conceptid="4264234" conceptname="Chloasma">Chloasma</span> or <span class="product-label-link" type="condition" conceptid="4264234" conceptname="Chloasma">melasma</span> that may persist when drug is discontinued; generalized <span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">erythema</span>; <span class="product-label-link" type="condition" conceptid="132702" conceptname="Erythema multiforme">erythema multiforme</span>; <span class="product-label-link" type="condition" conceptid="140176" conceptname="Erythema nodosum">erythema nodosum</span>; hemorrhagic <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">eruption</span>; loss of scalp hair; <span class="product-label-link" type="condition" conceptid="134718" conceptname="Hirsutism">hirsutism</span>; <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span>.</p>
<p></p>
<p><span class="Italics">Eyes <br></span></p>
<p>Retinal vascular <span class="product-label-link" type="condition" conceptid="4130722" conceptname="Thrombosis">thrombosis</span>; <span class="product-label-link" type="condition" conceptid="373786" conceptname="Abnormal vision">visual impairment</span>; intolerance to contact lenses.</p>
<p></p>
<p><span class="Italics">Central Nervous System (CNS) <br></span></p>
<p><span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span>; <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine</span>; <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>; <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>; <span class="product-label-link" type="condition" conceptid="440990" conceptname="Chorea">chorea</span>; <span class="product-label-link" type="condition" conceptid="436817" conceptname="Feeling nervous">nervousness</span>; mood disturbances; <span class="product-label-link" type="condition" conceptid="4184149" conceptname="Feeling irritable">irritability</span>; exacerbation of <span class="product-label-link" type="condition" conceptid="380378" conceptname="Epilepsy">epilepsy</span>, <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">dementia</span>; <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">paresthesia</span>; <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span>. <br></p>
<p><span class="Italics">Miscellaneous <br></span></p>
<p>Increase or decrease in weight; reduced carbohydrate tolerance; aggravation of <span class="product-label-link" type="condition" conceptid="4305376" conceptname="Porphyria">porphyria</span>; <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span>; <span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">arthralgias</span>; <span class="product-label-link" type="condition" conceptid="75635" conceptname="Cramp">leg cramps</span>; <span class="product-label-link" type="condition" conceptid="134736" conceptname="Backache">back pain</span>; changes in libido; <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span>, <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioedema</span>, anaphylactoid/<span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylactic reactions</span>; <span class="product-label-link" type="condition" conceptid="435510" conceptname="Hypocalcemia">hypocalcemia</span>; <span class="product-label-link" type="condition" conceptid="257581" conceptname="Exacerbation of asthma">exacerbation of asthma</span>; increased triglycerides; <span class="product-label-link" type="condition" conceptid="4042728" conceptname="Blood glucose abnormal">blood glucose abnormal</span>; <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span>; <span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">myalgia</span>; <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span>.</p>
</div>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="ID_a7e977e7-ccde-41b7-b1ff-c20dabfec0d3"></a><a name="section-7"></a><p></p>
<h1>7 DRUG INTERACTIONS</h1>
<p class="First">No drug-drug interaction studies have been conducted for Jinteli.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_d43d14ee-8fff-46f2-bf5f-7c8dfea877e1"></a><a name="section-7.1"></a><p></p>
<h2>7.1 Effect of Other Drugs on Combined Hormonal Products</h2>
<p class="First"><span class="Italics">Substances decreasing or increasing the plasma concentration of estrogen: In vitro </span>and <span class="Italics">in vivo </span>studies have shown that estrogens are metabolized partially by cytochrome P450 3A4 (CYP3A4). Therefore, inducers or inhibitors of CYP3A4 may affect estrogen drug metabolism. Inducers of CYP3A4 such as St. John’s wort (Hypericum perforatum) preparations, phenobarbital, carbamazepine and rifampin may decrease the plasma concentration of estrogens, possibly resulting in a decrease in therapeutic effects and/or changes in the <span class="product-label-link" type="condition" conceptid="195876" conceptname="Hematometra">uterine bleeding</span> profile. Inhibitors of CYP3A4 such as erythromycin, clarithromycin, ketoconazole, itraconazole, ritonavir and grapefruit juice may increase the plasma concentration of estrogens and may result in side effects. Coadministration of atorvastatin and certain hormonal products containing ethinyl estradiol increase AUC values for ethinyl estradiol approximately 20 percent. Ascorbic acid and acetaminophen may increase the plasma ethinyl estradiol concentration, possibly by inhibition of conjugation.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_592cdbb9-7b0e-4863-830a-383e631344a9"></a><a name="section-7.2"></a><p></p>
<h2>7.2 Effect of Combined Hormonal Products on Other Drugs</h2>
<p class="First">Combination hormonal products containing some synthetic estrogens (for example, ethinyl estradiol) may inhibit the metabolism of other compounds. Combination hormonal products have been shown to significantly decrease the plasma concentration of lamotrigine likely due to induction of lamotrigine glucuronidation. This may reduce <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizure</span> control; therefore, dosage adjustments of lamotrigine may be necessary.</p>
</div>
</div>
<div class="Section" data-sectionCode="43684-0">
<a name="ID_c7238087-f9d0-4ee8-a5e8-cf9365ec8737"></a><a name="section-8"></a><p></p>
<h1>8 USE IN SPECIFIC POPULATIONS</h1>
<div class="Section" data-sectionCode="42228-7">
<a name="ID_4755eb47-0714-4f8d-8d9f-27d3becaebea"></a><a name="section-8.1"></a><p></p>
<h2>8.1 Pregnancy</h2>
<p class="First">Jintelishould not be used during pregnancy <span class="Italics">[see Contraindications (</span><span class="Italics"><a href="#ID_a47e2a7b-c689-4deb-a20b-615691f468ac">4</a>)]</span>. There appears to be little or no increased risk of <span class="product-label-link" type="condition" conceptid="4029540" conceptname="Congenital anomaly">birth defects</span> in children born to women who have used estrogens and progestins as an oral contraceptive inadvertently during early pregnancy.</p>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="ID_c4c70d50-91ed-4a1b-a31c-08c3ab2ac37b"></a><a name="section-8.2"></a><p></p>
<h2>8.3 Nursing Mothers</h2>
<p class="First">Jinteli should not be used during lactation. Estrogen administration to nursing women has been shown to decrease the quantity and quality of the breast milk. Detectable amounts of estrogen and progestin have been identified in the breast milk of women receiving estrogen plus progestin therapy. Caution should be exercised when Jinteli is administered to a nursing woman.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="ID_b0bbf9d5-3205-4539-917f-ef56fb6fcb27"></a><a name="section-8.3"></a><p></p>
<h2>8.4 Pediatric Use</h2>
<p class="First">Jinteli is not indicated in children. Clinical studies have not been conducted in the pediatric population.</p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="ID_047b0de5-d7ac-4eb7-b76b-3d20764b0a03"></a><a name="section-8.4"></a><p></p>
<h2>8.5 Geriatric Use</h2>
<p class="First">There have not been sufficient numbers of geriatric women involved in clinical studies utilizing Jinteli<span class="Bold"><span class="Italics"></span></span>to determine whether those over 65 years of age differ from younger subjects in their response to Jinteli. <br></p>
<p><span class="Italics">The Women’s Health Initiative Studies <br></span></p>
<p>In the WHI estrogen plus progestin substudy (daily CE [0.625 mg] plus MPA [2.5 mg] versus placebo), there was a higher relative risk of nonfatal <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span> and invasive breast cancer in women greater than 65 years of age <span class="Italics">[see Clinical Studies (</span><span class="Italics"><a href="#ID_5296d075-c832-4f39-b7c9-2082c7c60538">14.5</a>)]</span>. <br></p>
<p>In the WHI estrogen-alone substudy (daily CE [0.625 mg]-alone versus placebo), there was a higher relative risk of <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span> in women greater than 65 years of age <span class="Italics">[see Clinical Studies (</span><span class="Italics"><a href="#ID_5296d075-c832-4f39-b7c9-2082c7c60538">14.5</a>)]</span>. <br></p>
<p><span class="Italics">The Women’s Health Initiative Memory Study <br></span></p>
<p>In the WHIMS ancillary studies of postmenopausal women 65 to 79 years of age, there was an increased risk of developing probable <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">dementia</span> in women receiving estrogen plus progestin or estrogen-alone when compared to placebo <span class="Italics">[see Warnings and Precautions (</span><span class="Italics"><a href="#ID_b6c93caa-3b1a-4955-93b6-2c1d7d79d3e1">5.3</a>), and Clinical Studies (<a href="#ID_6085a306-55d1-4c11-9aab-45c08a1b53fe">14.6</a>)]</span>. <br></p>
<p>Since both ancillary studies were conducted in women 65 to 79 years of age, it is unknown whether these findings apply to younger postmenopausal women<span class="Sup">8 </span><span class="Italics">[see Warnings and Precautions (</span><span class="Italics"><a href="#ID_b6c93caa-3b1a-4955-93b6-2c1d7d79d3e1">5.3</a>), and Clinical Studies (<a href="#ID_6085a306-55d1-4c11-9aab-45c08a1b53fe">14.6</a>)]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_8f38b03a-d5b3-40ae-a7f7-d7f1dce11068"></a><a name="section-8.5"></a><p></p>
<h2>8.6 <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></h2>
<p class="First">The effect of <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> on the pharmacokinetics of Jinteli has not been studied.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_e7d42d16-84f4-4866-b8b7-94c5815b57ad"></a><a name="section-8.6"></a><p></p>
<h2>8.7 <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span></h2>
<p class="First">The effect of <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> on the pharmacokinetics of Jinteli has not been studied.</p>
</div>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="ID_4b69b5fd-c788-46dc-90b1-94fa85186703"></a><a name="section-9"></a><p></p>
<h1>10 OVERDOSAGE</h1>
<p class="First">Overdosage of estrogen plus progestin may cause <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="4208409" conceptname="Breast tenderness">breast tenderness</span>, <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span>, <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">drowsiness</span> and <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span>, and <span class="product-label-link" type="condition" conceptid="4161407" conceptname="Withdrawal bleeding">withdrawal bleeding</span> may occur in women. Treatment of <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> consists of discontinuation of Jinteli<span class="Bold"><span class="Italics"></span></span>with institution of appropriate symptomatic care.</p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="ID_ca2c4787-673a-4826-adb4-309ac3abd847"></a><a name="section-10"></a><p></p>
<h1>11 DESCRIPTION</h1>
<p class="First">Jinteli<span class="Sup">®</span> (norethindrone acetate and ethinyl estradiol tablets USP) is a continuous dosage regimen of a progestin-estrogen combination for oral administration.</p>
<p>Each white tablet contains 1 mg norethindrone acetate, USP [19-Norpregn-4-en-20-yn-3-one, 17-(acetyloxy)-, (17α)-] and 5 mcg ethinyl estradiol, USP [19-Norpregna-1,3,5(10)-trien-20-yne-3, 17-diol, (17α)-]. Each tablet also contains the following ingredients:  calcium stearate, lactose monohydrate, microcrystalline cellulose, pregelatinized corn starch, and sodium starch glycolate.<br></p>
<p>The structural formulas are as follows:<br></p>
<p>          Norethindrone Acetate, USP	              Ethinyl Estradiol, USP</p>
<div class="Figure">
<a name="id123202339"></a><img alt="structural formulas" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=d667ca75-1a17-43fc-9077-f25ce0908f8d&amp;name=image-01.jpg">
</div>
<p>       C<span class="Sub">22</span>H<span class="Sub">28</span>O<span class="Sub">3</span>       M.W. 340.47                           C<span class="Sub">20</span>H<span class="Sub">24</span>O<span class="Sub">2</span>        M.W. 296.41</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="ID_2a0560ad-8b41-4ee2-a0de-01cbedfba9c7"></a><a name="section-11"></a><p></p>
<h1>12 CLINICAL PHARMACOLOGY</h1>
<div class="Section" data-sectionCode="43679-0">
<a name="ID_12ed5c23-2eda-4038-990f-b77228cc725c"></a><a name="section-11.1"></a><p></p>
<h2>12.1 Mechanism of Action</h2>
<p class="First">Endogenous estrogens are largely responsible for the development and maintenance of the female reproductive system and secondary sexual characteristics. Although circulating estrogens exist in a dynamic equilibrium of metabolic interconversions, estradiol is the principal intracellular human estrogen and is substantially more potent than its metabolites, estrone and estriol, at the receptor level. <br></p>
<p>The primary source of estrogen in normally cycling adult women is the ovarian follicle, which secretes 70 to 500 mcg of estradiol daily, depending on the phase of the menstrual cycle. After <span class="product-label-link" type="condition" conceptid="4059477" conceptname="Menopause">menopause</span>, most endogenous estrogen is produced by conversion of androstenedione, which is secreted by the adrenal cortex, to estrone in the peripheral tissues. Thus, estrone and the sulfate conjugated form, estrone sulfate, are the most abundant circulating estrogens in postmenopausal women. The pharmacologic effects of ethinyl estradiol are similar to those of endogenous estrogens.</p>
<p></p>
<p>Estrogens act through binding to nuclear receptors in estrogen-responsive tissues. To date, two estrogen receptors have been identified. These vary in proportion from tissue to tissue. <br></p>
<p>Circulating estrogens modulate the pituitary secretion of the gonadotropins, luteinizing hormone (LH) and FSH through a negative feedback mechanism. Estrogens act to reduce the elevated levels of these hormones seen in postmenopausal women. <br></p>
<p>Progestin compounds enhance cellular differentiation and generally oppose the actions of estrogens by decreasing estrogen receptor levels, increasing local metabolism of estrogens to less active metabolites, or inducing gene products that blunt cellular responses to estrogen. Progestins exert their effects in target cells by binding to specific progesterone receptors that interact with progesterone response elements in target genes. Progesterone receptors have been identified in the female reproductive tract, breast, pituitary, hypothalamus, bone, skeletal tissue and central nervous system. Progestins produce similar endometrial changes to those of the naturally occurring hormone progesterone.</p>
</div>
<div class="Section" data-sectionCode="43681-6">
<a name="ID_e83d3a53-703d-4606-aaa0-9dcb3d8a46cb"></a><a name="section-11.2"></a><p></p>
<h2>12.2 Pharmacodynamics</h2>
<p class="First">Currently, there is no pharmacodynamic data known for Jinteli.</p>
</div>
<div class="Section" data-sectionCode="43682-4">
<a name="ID_d9384d5e-e151-49ea-a703-cd27cee73237"></a><a name="section-11.3"></a><p></p>
<h2>12.3 Pharmacokinetics</h2>
<p class="First"><span class="Italics">Absorption <br></span></p>
<p>Norethindrone acetate (NA) is completely deacetylated to norethindrone after oral administration, and the disposition of norethindrone acetate is indistinguishable from that of orally administered norethindrone. Norethindrone acetate and ethinyl estradiol (EE) are absorbed from Jinteli<span class="Bold"><span class="Italics"></span></span>tablets, with maximum plasma concentrations of norethindrone and ethinyl estradiol generally occurring 1 to 2 hours postdose. Both are subject to first-pass metabolism after oral dosing, resulting in an absolute bioavailability of approximately 64 percent for norethindrone and 55 percent for ethinyl estradiol. Bioavailability of Jinteli<span class="Bold"><span class="Italics"></span></span>tablets is similar to that from solution for norethindrone and slightly less for ethinyl estradiol. Administration of Jinteli tablets with a high fat meal decreases rate but not extent of ethinyl estradiol absorption. The extent of norethindrone absorption is increased by 27 percent following administration of Jinteli<span class="Bold"><span class="Italics"></span></span>tablets with food.</p>
<p></p>
<p>The full pharmacokinetic profile of Jinteli<span class="Italics"></span>tablets was not characterized due to assay sensitivity limitations. However, the multiple-dose pharmacokinetics were studied at a dose of 1 mg NA/10 mcg EE in 18 postmenopausal women. Mean plasma concentrations are shown below (<a href="#Figure_1">Figure 1</a>) and pharmacokinetic parameters are found in <a href="#Table_2">Table 2</a>. Based on a population pharmacokinetic analysis, mean steady-state concentrations of norethindrone for 1 mg NA/5 mcg EE and 1/10 are slightly more than proportional to dose when compared to 0.5 mg NA/2.5 mcg EE tablets. It can be explained by higher SHBG concentrations. Mean steady-state plasma concentrations of ethinyl estradiol for the Jinteli<span class="Italics"></span>0.5/2.5 tablets and Jinteli<span class="Italics"></span>1/5 tablets are proportional to dose, but there is a less than proportional increase in steady-state concentrations for the NA/EE 1/10 tablet.<br></p>
<p><br><span class="Bold">Figure 1. Mean Steady-State (Day 87) Plasma Norethindrone and Ethinyl Estradiol</span></p>
<p><span class="Bold">Concentrations Following Continuous Oral Administration of 1 mg NA/10 mcg EE Tablets</span><br><a name="id123202724"></a><img alt="Figure 1" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=d667ca75-1a17-43fc-9077-f25ce0908f8d&amp;name=image-02.jpg"></p>
<table width="100%">
<col width="22%">
<col width="16%">
<col width="15%">
<col width="16%">
<col width="16%">
<col width="15%">
<tfoot><tr><td colspan="6" align="left"><dl class="Footnote">
<dt><a name="footnote-2" href="#footnote-reference-2">*</a></dt>
<dd>C<span class="Sub">max</span> = Maximum plasma concentrations; t<span class="Sub">max</span> = time of C<span class="Sub">max</span>; AUC (0 to 24) = Area under the plasma concentration-time curve over the dosing interval; and CL/F = Apparent oral clearance; t<span class="Sub">1/2 </span>= Elimination half-life</dd>
<dt><a name="footnote-3" href="#footnote-reference-3">†</a></dt>
<dd>ND = Not Determined</dd>
</dl></td></tr></tfoot>
<tbody class="Headless">
<tr class="First">
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr><td align="center" colspan="6"><p class="First"><span class="Bold">Table 2. Mean (SD) Single-Dose (Day 1) and Steady-State (Day 87) Pharmacokinetic Parameters</span><a name="footnote-reference-2" href="#footnote-2" class="Sup">*</a><span class="Bold">Following Administration of 1 mg NA/10 mcg EE Tablets</span></p></td></tr>
<tr>
<td class="Botrule Toprule"></td>
<td class="Botrule Toprule"><p class="First">C<span class="Sub">max</span></p></td>
<td class="Botrule Toprule"><p class="First">t<span class="Sub">max</span></p></td>
<td class="Botrule Toprule"><p class="First">AUC (0 to 24)</p></td>
<td class="Botrule Toprule"><p class="First">CL/F</p></td>
<td class="Botrule Toprule"><p class="First">t<span class="Sub">1/2</span></p></td>
</tr>
<tr>
<td class="Botrule"><p class="First"><span class="Bold">NORETHINDRONE</span></p></td>
<td class="Botrule Toprule"><p class="First">ng/mL</p></td>
<td class="Botrule Toprule"><p class="First">hr</p></td>
<td class="Botrule Toprule"><p class="First">ng·hr/mL</p></td>
<td class="Botrule Toprule"><p class="First">mL/min</p></td>
<td class="Botrule Toprule"><p class="First">hr</p></td>
</tr>
<tr>
<td class="Botrule">
<p class="First">Day 1</p>
<p>Day 87</p>
</td>
<td class="Botrule Toprule">
<p class="First">6 (3.3)</p>
<p>10.7 (3.6)</p>
</td>
<td class="Botrule Toprule">
<p class="First">1.8 (0.8)</p>
<p>1.8 (0.8)</p>
</td>
<td class="Botrule Toprule">
<p class="First">29.7 (16.5)</p>
<p>81.8 (36.7)</p>
</td>
<td class="Botrule Toprule">
<p class="First">588 (416)</p>
<p>226 (139)</p>
</td>
<td class="Botrule Toprule">
<p class="First">10.3 (3.7)</p>
<p>13.3 (4.5)</p>
</td>
</tr>
<tr>
<td class="Botrule"><p class="First"><span class="Bold">ETHINYL ESTRADIOL</span></p></td>
<td class="Botrule Toprule"><p class="First">pg/mL</p></td>
<td class="Botrule Toprule"><p class="First">hr</p></td>
<td class="Botrule Toprule"><p class="First">pg·hr/mL</p></td>
<td class="Botrule Toprule"><p class="First">mL/min</p></td>
<td class="Botrule Toprule"><p class="First">hr</p></td>
</tr>
<tr>
<td class="Botrule">
<p class="First">Day 1</p>
<p>Day 87</p>
</td>
<td class="Botrule Toprule">
<p class="First">33.5 (13.7)</p>
<p>38.3 (11.9)</p>
</td>
<td class="Botrule Toprule">
<p class="First">2.2 (1)</p>
<p>1.8 (0.7)</p>
</td>
<td class="Botrule Toprule">
<p class="First">339 (113)</p>
<p>471 (132)</p>
</td>
<td class="Botrule Toprule">
<p class="First">ND<a name="footnote-reference-3" href="#footnote-3" class="Sup">†</a></p>
<p>383 (119)</p>
</td>
<td class="Botrule Toprule">
<p class="First">ND<a href="#footnote-3" class="Sup">†</a></p>
<p>23.9 (7.1)</p>
</td>
</tr>
<tr class="Last"><td colspan="6"></td></tr>
</tbody>
</table>
<p>Based on a population pharmacokinetic analysis, average steady-state concentrations (Css) of norethindrone and ethinyl estradiol for Jinteli<span class="Bold"><span class="Italics"></span></span>1/5 tablets are estimated to be 2.6 ng/mL and 11.4 pg/mL, respectively. Css values of norethindrone and ethinyl estradiol for Jinteli<span class="Bold"><span class="Italics"></span></span>0.5/2.5 tablets are estimated to be 1.1 ng/mL and 5.4 ng/mL, respectively. <br></p>
<p>The pharmacokinetics of ethinyl estradiol and norethindrone acetate were not affected by age, (age range 40 to 62 years), in the postmenopausal population studied. <br></p>
<p><span class="Italics">Distribution <br></span></p>
<p>The distribution of exogenous estrogens is similar to that of endogenous estrogens. Estrogens are widely distributed in the body and are generally found in higher concentrations in the sex hormone target organs. Estrogens circulate in the blood largely bound to SHBG and albumin.<br></p>
<p>Volume of distribution of norethindrone and ethinyl estradiol ranges from 2 to 4 L/kg. Plasma protein binding of both steroids is extensive (greater than 95 percent); norethindrone binds to both albumin and SHBG, whereas ethinyl estradiol binds only to albumin. Although ethinyl estradiol does not bind to SHBG, it induces SHBG synthesis. <br></p>
<p><span class="Italics">Metabolism <br></span></p>
<p><span class="Italics">Excretion </span></p>
<p><br>Estradiol, estrone, and estriol are excreted in the urine along with glucuronide and sulfate conjugates. </p>
<p>Norethindrone and ethinyl estradiol are excreted in both urine and feces, primarily as metabolites. Plasma clearance values for norethindrone and ethinyl estradiol are similar (approximately 0.4 L/hr/kg). Steady-state elimination half-lives of norethindrone and ethinyl estradiol following administration of 1 mg NA/10 mcg EE tablets are approximately 13 hours and 24 hours, respectively. <br></p>
<p><span class="Italics">Use in Specific Populations <br></span></p>
</div>
</div>
<div class="Section" data-sectionCode="43680-8">
<a name="ID_673254b6-c0b4-499f-a322-5c4d699d25fb"></a><a name="section-12"></a><p></p>
<h1>13 NONCLINICAL TOXICOLOGY</h1>
<div class="Section" data-sectionCode="34083-6">
<a name="ID_7a39a838-419d-485e-9ecf-875e23f5793f"></a><a name="section-12.1"></a><p></p>
<h2>13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</h2>
<p class="First">Long-term continuous administration of natural and synthetic estrogens in certain animal species increases the frequency of carcinomas of the breast, uterus, cervix, vagina, testis, and liver.</p>
</div>
</div>
<div class="Section" data-sectionCode="34092-7">
<a name="ID_c2537c77-1812-41ce-a948-ac40b1ff72ff"></a><a name="section-13"></a><p></p>
<h1>14 CLINICAL STUDIES</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_cecd88ea-d432-436c-9039-71f34bdfc433"></a><a name="section-13.1"></a><p></p>
<h2>14.1 Effects on Vasomotor Symptoms</h2>
<p class="First">A 12 week placebo-controlled, multicenter, randomized clinical trial was conducted in 266 symptomatic women who had at least 56 moderate to severe <span class="product-label-link" type="condition" conceptid="4113666" conceptname="Menopausal flushing">hot flushes</span> during the week prior to randomization. On average, patients had 12 <span class="product-label-link" type="condition" conceptid="4113666" conceptname="Menopausal flushing">hot flushes</span> per day upon study entry. <br></p>
<p>A total of 66 women were randomized to receive Jinteli 1/5 and 66 women were randomized to the placebo group. Jinteli<span class="Bold"><span class="Italics"></span></span>1/5 was shown to be statistically better than placebo at weeks 4, and 12 for relief of the frequency of moderate to severe vasomotor symptoms (see <a href="#Table_3">Table 3</a>). In <a href="#Table_4">Table 4</a><span class="Underline">,</span>Jinteli<span class="Bold"><span class="Italics"></span></span>1/5 was shown to be statistically better than placebo at weeks 4 and 12 for relief of the severity of moderate to severe vasomotor symptoms.</p>
<table width="100%">
<col width="25%">
<col width="25%">
<col width="25%">
<col width="25%">
<tbody class="Headless">
<tr class="First"><td class="Botrule" align="center" colspan="4">
<p class="First"><span class="Bold">Table 3. Mean Change from Baseline in the Number of Moderate to Severe</span></p>
<p><span class="Bold">Vasomotor Symptoms per Week – ITT Population, LOCF</span></p>
</td></tr>
<tr>
<td class="Botrule Toprule"><p class="First"><span class="Bold">Visit</span></p></td>
<td class="Botrule Toprule" align="center">
<p class="First"><span class="Bold">Placebo</span></p>
<p><span class="Bold">(N = 66)</span></p>
</td>
<td class="Botrule Toprule" align="center">
<p class="First"><span class="Bold">Jinteli</span></p>
<p><span class="Bold">0.5/2.5</span></p>
<p><span class="Bold">(N = 67)</span></p>
</td>
<td class="Botrule Toprule" align="center">
<p class="First"><span class="Bold">Jinteli</span></p>
<p><span class="Bold">1/5</span></p>
<p><span class="Bold">(N = 66)</span></p>
</td>
</tr>
<tr>
<td class="Toprule">
<p class="First"><span class="Bold">Baseline </span><a href="#_Ref395609203">1</a></p>
<p>Mean (SD)</p>
</td>
<td class="Toprule" align="center"><p class="First">76.5 (21.4)</p></td>
<td class="Toprule" align="center"><p class="First">77.6 (26.5)</p></td>
<td class="Toprule" align="center"><p class="First">70 (16.6)</p></td>
</tr>
<tr>
<td>
<p class="First"><span class="Bold">Week 4</span></p>
<p>Mean (SD)</p>
<p>Mean Change from Baseline (SD) </p>
<p>p-Value vs. Placebo</p>
<p>(95 percent CI)<a href="#_Ref395609786">3</a></p>
</td>
<td align="center">
<p class="First"><br>39.4 (27.6)</p>
<p>-37 (26.6)</p>
</td>
<td align="center">
<p class="First"><br>30.2 (26.1)</p>
<p>-47.4<a href="#_Ref395609282">2</a> (26.1)</p>
<p>0.041 (-20, -1)</p>
</td>
<td align="center">
<p class="First"><br>20.4 (22.7)</p>
<p>-49.6<a href="#_Ref395609282">2</a>(22.1)</p>
<p>&lt;0.001 (-22,-6)</p>
</td>
</tr>
<tr>
<td class="Botrule">
<p class="First"><span class="Bold">Week  12</span></p>
<p>Mean (SD)</p>
<p>Mean Change from</p>
<p>Baseline (SD)</p>
<p>p-Value vs. Placebo (95 percent CI)<a href="#_Ref395609786">3</a></p>
</td>
<td class="Botrule" align="center">
<p class="First"><br>31.1 (27)</p>
<p>-45.3 (30.2)</p>
</td>
<td class="Botrule" align="center">
<p class="First"><br>13.8 (20.4)</p>
<p>-63.8<a href="#_Ref395609282">2</a> (27.5)</p>
<p>&lt;0.001 (-27, -7)</p>
</td>
<td class="Botrule" align="center">
<p class="First"><br>11.3 (18.9)</p>
<p>-58.7<a href="#_Ref395609282">2</a> (23.1)</p>
<p>&lt;0.001 (-25, -5)</p>
</td>
</tr>
<tr class="Last"><td class="Toprule" colspan="4"></td></tr>
</tbody>
</table>
<table width="100%">
<col width="25%">
<col width="25%">
<col width="25%">
<col width="25%">
<tfoot><tr><td colspan="4" align="left"><dl class="Footnote">
<dt><a name="footnote-4" href="#footnote-reference-4">*</a></dt>
<dd>ANCOVA – Analysis of Covariance model where the observation variable is change from baseline; independent variables include treatment, center and baseline as covariate. The 95 percent CI- Mann- Whitney confidence interval for the difference between means (not stratified by center).</dd>
</dl></td></tr></tfoot>
<tbody class="Headless">
<tr class="First Toprule"><td class="Botrule" align="center" colspan="4">
<p class="First"><span class="Bold">Table 4. Mean Change from Baseline in the Daily Severity Score of Moderate</span></p>
<p><span class="Bold">to Severe Vasomotor Symptoms per Week – ITT Population, LOCF</span></p>
</td></tr>
<tr>
<td class="Botrule Toprule"><p class="First"><span class="Bold">Visit</span></p></td>
<td class="Botrule Toprule" align="center">
<p class="First"><span class="Bold">Placebo</span></p>
<p><span class="Bold">(N = 66)</span></p>
</td>
<td class="Botrule Toprule" align="center">
<p class="First"><span class="Bold">Jinteli</span></p>
<p><span class="Bold">0.5/2.5</span></p>
<p><span class="Bold">(N = 67)</span></p>
</td>
<td class="Botrule Toprule" align="center">
<p class="First"><span class="Bold">Jinteli</span></p>
<p><span class="Bold">1/5</span></p>
<p><span class="Bold">N = 66</span></p>
</td>
</tr>
<tr>
<td class="Toprule">
<p class="First"><span class="Bold">Baseline </span><a href="#_Ref395606087">1</a></p>
<p>Mean (SD)</p>
</td>
<td class="Toprule" align="center"><p class="First">2.49 (0.26)</p></td>
<td class="Toprule" align="center"><p class="First">2.48 (0.22)</p></td>
<td class="Toprule" align="center"><p class="First">2.47 (0.23)</p></td>
</tr>
<tr>
<td>
<p class="First"><span class="Bold">Week 4</span></p>
<p>Mean (SD)</p>
<p>Mean Change from Baseline (SD)</p>
<p>p-Value vs. Placebo</p>
<p>(95 percent CI)<a name="footnote-reference-4" href="#footnote-4" class="Sup">*</a></p>
</td>
<td align="center">
<p class="First"><br>2.13 (0.74)</p>
<p>-0.36 (0.68)</p>
<p><br>-</p>
</td>
<td align="center">
<p class="First"><br>1.88 (0.89)</p>
<p>-0.59 (0.83)</p>
<p><br>0.13 (0.3, 0)</p>
</td>
<td align="center">
<p class="First"><br>1.45 (1.03)</p>
<p>-1.02<a href="#_Ref395613448">2</a> (1.06)</p>
<p><br>&lt;0.001 (-0.9, -0.2)</p>
</td>
</tr>
<tr>
<td>
<p class="First"><span class="Bold">Week 5</span></p>
<p>Mean (SD)</p>
<p>Mean Change from Baseline (SD)</p>
<p>p -Value vs. Placebo  (95 percent CI)<a href="#footnote-4" class="Sup">*</a><span class="Sup"></span></p>
</td>
<td align="center">
<p class="First"><br>2.06 (0.79)</p>
<p>-0.44 (0.74)</p>
<p><br>-</p>
</td>
<td align="center">
<p class="First"><br>1.68 (0.99)</p>
<p>-0.80<a href="#_Ref395613448">2</a> (0.94)</p>
<p><br>0.041 (-0.4, -0)</p>
</td>
<td align="center">
<p class="First"><br>1.23 (1.03)</p>
<p>-1.24<a href="#_Ref395613448">2</a> (1.07)</p>
<p><br>&lt;0.001 (-1.2, -0.3)</p>
</td>
</tr>
<tr>
<td class="Botrule">
<p class="First"><span class="Bold">Week 12</span></p>
<p>Mean (SD)</p>
<p>Mean Change from Baseline (SD)</p>
<p>p-Value vs. Placebo   (95 percent CI)<a href="#footnote-4" class="Sup">*</a></p>
</td>
<td class="Botrule" align="center">
<p class="First"><br>1.82 (1.03)</p>
<p>-0.67 (1.02)</p>
<p><br>-</p>
</td>
<td class="Botrule" align="center">
<p class="First"><br>1.22 (1.11)</p>
<p>-1.26<a href="#_Ref395613448">2</a> (1.08)</p>
<p><br>0.002 (-0.9, -0.2)</p>
</td>
<td class="Botrule" align="center">
<p class="First"><br>1.02 (1.16)</p>
<p>-1.45<a href="#_Ref395613448">2</a> (1.19)</p>
<p><br>&lt;0.001 (-1.4, -0.3)</p>
</td>
</tr>
<tr class="Botrule Last"><td class="Toprule" colspan="4"></td></tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_c4d7496a-71ef-43e8-9805-c9e3b3c40f01"></a><a name="section-13.2"></a><p></p>
<h2>14.2 Effects on the Endometrium</h2>
<p class="First">A 2 year, placebo-controlled, multicenter, randomized clinical trial was conducted to determine the safety and efficacy of Jinteli on maintaining bone mineral density, protecting the endometrium, and to determine effects on lipids. A total of 1,265 women were enrolled and randomized to either placebo, 0.2 mg NA/1 mcg ethinyl estradiol (NA/EE 0.2/1), 0.5 mg NA/2.5 mcg EE (NA/EE 0.5/2.5), Jinteli 1/5 and 1 mg NA/10 mcg EE (NA/EE 1/10) or matching unopposed EE doses (1, 2.5, 5, or 10 mcg) for a total of 9 treatment groups. All participants received 1000 mg of calcium supplementation daily. Of the 1,265 women randomized to the various treatment arms of this study, 137 were randomized to placebo, 146 to Jinteli<span class="Bold"><span class="Italics"></span></span>1/5, 136 to NA/EE 0.5/2.5 and 141 to EE 5 mcg and 137 to EE 2.5 mcg. Of these, 134 placebo, 143 Jinteli 1/5, 136 NA/EE 0.5/2.5, 139 EE 5 mcg and 137 EE 2.5 mcg had a baseline endometrial result. Baseline biopsies were classified as normal (in approximately 95 percent of subjects), or insufficient tissue (in approximately 5 percent of subjects). Follow-up biopsies were obtained in approximately 70 to 80 percent of patients in each arm after 12 and 24 months of therapy. Results for Jinteli<span class="Bold"><span class="Italics"></span></span>1/5 and appropriate comparators are shown in <a href="#Table_5">Table 5</a>.</p>
<table width="100%">
<col width="41%">
<col width="17%">
<col width="10%">
<col width="10%">
<col width="11%">
<col width="11%">
<tfoot><tr><td colspan="6" align="left"><dl class="Footnote">
<dt><a name="footnote-5" href="#footnote-reference-5">*</a></dt>
<dd>All patients with <span class="product-label-link" type="condition" conceptid="200775" conceptname="Endometrial hyperplasia">endometrial hyperplasia</span> were carried forward for all time points.</dd>
</dl></td></tr></tfoot>
<tbody class="Headless">
<tr class="First Toprule"><td class="Botrule" align="center" colspan="6">
<p class="First"><span class="Bold">Table 5. Endometrial Biopsy Results After 12 and 24 Months of Treatment</span></p>
<p><span class="Bold">(CHART Study, 376- 359)</span></p>
</td></tr>
<tr>
<td class="Toprule"><p class="First"><span class="Bold">Endometrial Status</span></p></td>
<td class="Toprule" align="center"><p class="First"><span class="Bold">Placebo</span></p></td>
<td class="Botrule Toprule" align="center" colspan="2"><p class="First"><span class="Bold">Jinteli</span></p></td>
<td class="Botrule Toprule" align="center" colspan="2"><p class="First"><span class="Bold">EE Alone</span></p></td>
</tr>
<tr>
<td class="Botrule"></td>
<td class="Botrule"></td>
<td class="Botrule" align="center"><p class="First"><span class="Bold">0.5/2.5</span></p></td>
<td class="Botrule" align="center"><p class="First"><span class="Bold">1/5</span></p></td>
<td class="Botrule" align="center"><p class="First"><span class="Bold">2.5 mcg</span></p></td>
<td class="Botrule" align="center"><p class="First"><span class="Bold">5 mcg</span></p></td>
</tr>
<tr>
<td class="Toprule"><p class="First"><span class="Bold">Number of Patients Biopsied at Baseline</span></p></td>
<td class="Toprule" align="center"><p class="First">N = 134</p></td>
<td class="Toprule" align="center"><p class="First">N = 136</p></td>
<td class="Toprule" align="center"><p class="First">N = 143</p></td>
<td class="Toprule" align="center"><p class="First">N = 137</p></td>
<td class="Toprule" align="center"><p class="First">N = 139</p></td>
</tr>
<tr>
<td>
<p class="First"><span class="Bold">Month 12 (Percent Patients)</span></p>
<p>Patients Biopsied (percent)</p>
<p>                 Insufficient Tissue</p>
<p>                 Atrophic Tissue</p>
<p>                 Proliferative Tissue</p>
<p>                 <span class="product-label-link" type="condition" conceptid="200775" conceptname="Endometrial hyperplasia">Endometrial Hyperplasia</span><a name="footnote-reference-5" href="#footnote-5" class="Sup">*</a></p>
</td>
<td align="center">
<p class="First">113 (84)</p>
<p>30</p>
<p>60</p>
<p>23</p>
<p>0</p>
</td>
<td align="center">
<p class="First">103 (74)</p>
<p>34</p>
<p>41</p>
<p>28</p>
<p>0</p>
</td>
<td align="center">
<p class="First">110 (77)</p>
<p>45</p>
<p>41</p>
<p>24</p>
<p>0</p>
</td>
<td align="center">
<p class="First">100 (73)</p>
<p>20</p>
<p>15</p>
<p>65</p>
<p>0</p>
</td>
<td align="center">
<p class="First">114 (82)</p>
<p>20</p>
<p>2</p>
<p>91</p>
<p>1</p>
</td>
</tr>
<tr class="Botrule Last">
<td class="Botrule">
<p class="First"><span class="Bold">Month 24 (Percent Patients)</span></p>
<p>Patients Biopsied (percent)</p>
<p>                 Insufficient Tissue</p>
<p>                 Atrophic Tissue</p>
<p>                 Proliferative Tissue</p>
<p>                 <span class="product-label-link" type="condition" conceptid="200775" conceptname="Endometrial hyperplasia">Endometrial Hyperplasia</span><a href="#footnote-5" class="Sup">*</a></p>
</td>
<td class="Botrule" align="center">
<p class="First">94 (70)</p>
<p>35</p>
<p>38</p>
<p>20</p>
<p>1</p>
</td>
<td class="Botrule" align="center">
<p class="First">99 (73)</p>
<p>42</p>
<p>30</p>
<p>27</p>
<p>0</p>
</td>
<td class="Botrule" align="center">
<p class="First">102 (71)</p>
<p>37</p>
<p>33</p>
<p>32</p>
<p>0</p>
</td>
<td class="Botrule" align="center">
<p class="First">89 (65)</p>
<p>23</p>
<p>6</p>
<p>60</p>
<p>0</p>
</td>
<td class="Botrule" align="center">
<p class="First">107 (77)</p>
<p>17</p>
<p>2</p>
<p>86</p>
<p>2</p>
</td>
</tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_c71f9c74-4abe-4fce-a80c-5e4f30a67855"></a><a name="section-13.3"></a><p></p>
<h2>14.3 Effects on <span class="product-label-link" type="condition" conceptid="195876" conceptname="Hematometra">Uterine Bleeding</span> or Spotting</h2>
<p class="First">The cumulative incidence of <span class="product-label-link" type="condition" conceptid="443800" conceptname="Amenorrhea">amenorrhea</span>, defined as no <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> or spotting obtained from subject recall, was evaluated over 12 months for Jinteli<span class="Bold"><span class="Italics"></span></span>1/5 and placebo arms. Results are shown in <a href="#Figure_2">Figure 2</a>.<br><br><span class="Bold">Figure 2. Patients With Cumulative <span class="product-label-link" type="condition" conceptid="443800" conceptname="Amenorrhea">Amenorrhea</span> Over Time: Intent-to-Treat Population, Last Observation Carried Forward</span><br><a name="id123202765"></a><img alt="Figure 2" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=d667ca75-1a17-43fc-9077-f25ce0908f8d&amp;name=image-03.jpg"></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_f4876d22-1c9b-414f-8e01-4132985196cd"></a><a name="section-13.4"></a><p></p>
<h2>14.4 Effect on Bone Mineral Density</h2>
<p class="First">In the 2 year study, trabecular BMD was assessed at lumbar spine using quantitative computed tomography. A total of 419 postmenopausal primarily Caucasian women, 40 to 64 years of age, with intact uteri and non-osteoporotic bone mineral densities were randomized (1:1:1) to Jinteli<span class="Bold"><span class="Italics"></span></span>1/5, NA/EE 0.5/2.5 or placebo. Approximately 75 percent of the subjects in each group completed the two year study. All patients received 1000 mg calcium in divided doses. Vitamin D was not supplemented. <br></p>
<p>As shown in <a href="#Figure_3">Figure 3</a>, women treated with Jinteli<span class="Bold"><span class="Italics"></span></span>1/5 had an average increase of 3.1 percent in lumbar spine BMD from baseline to Month 24. Women treated with placebo had average decreases of -6.3 percent in spinal BMD from baseline to Month 24. The differences in the changes from baseline to Month 24 in the Jinteli<span class="Bold"><span class="Italics"></span></span>1/5 group compared with the placebo group was statistically significant.<br></p>
<p><span class="Bold">Figure 3. Mean Percent Change (+ SE) From Baseline in Volumetric Bone Mineral </span></p>
<p><span class="Bold">Density* at Lumbar Spine Measured by Quantitative Computed Tomography after 12 and 24 Months of Treatment (Intent-to-Treat Population)</span><br><br><a name="id128514896"></a><img alt="Figure 3" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=d667ca75-1a17-43fc-9077-f25ce0908f8d&amp;name=image-04.jpg"></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_5296d075-c832-4f39-b7c9-2082c7c60538"></a><a name="section-13.5"></a><p></p>
<h2>14.5 Women’s Health Initiative Studies</h2>
<p class="First">The WHI enrolled approximately 27,000 predominantly healthy postmenopausal women in two substudies to assess the risks and benefits of daily oral CE (0.625 mg)-alone or in combination with MPA (2.5 mg) compared to placebo in the prevention of certain chronic diseases. The primary endpoint was the incidence of CHD (defined as nonfatal MI, silent MI and CHD <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>), with invasive breast cancer as the primary adverse outcome. A “global index? included the earliest occurrence of CHD, invasive breast cancer, <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span>, PE, endometrial cancer (only in the CE plus MPA substudy), colorectal cancer, <span class="product-label-link" type="condition" conceptid="4138412" conceptname="Fracture of proximal end of femur">hip fracture</span>, or <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> due to other cause. The study did not evaluate the effects of CE plus MPA or CE-alone on <span class="product-label-link" type="condition" conceptid="439082" conceptname="Menopausal syndrome">menopausal symptoms</span>.</p>
<p></p>
<p><span class="Italics">WHI Estrogen Plus Progestin Substudy <br></span></p>
<p>The WHI estrogen plus progestin substudy was stopped early. According to the predefined stopping rule, after an average follow-up of 5.6 years of treatment, the increased risk of invasive breast cancer and cardiovascular events exceeded the specified benefits included in the “global index?. The absolute excess risk of events included in the “global index? was 19 per 10,000 women-years. <br></p>
<p>For those outcomes included in the WHI “global index? that reached statistical significance after 5.6 years of follow-up, the absolute excess risks per 10,000 women-years in the group treated with CE plus MPA were 7 more CHD events, 8 more <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">strokes</span>, 10 more PEs, and 8 more invasive breast cancers, while the absolute risk reductions per 10,000 women-years were 6 fewer colorectal cancers and 5 fewer <span class="product-label-link" type="condition" conceptid="4138412" conceptname="Fracture of proximal end of femur">hip fractures</span>. <br></p>
<p>Results of the CE plus MPA substudy, which included 16,608 women (average 63 years of age, range 50 to 79; </p>
<p>83.9 percent White, 6.8 percent Black, 5.4 percent Hispanic, 3.9 percent Other) are presented in <a href="#Table_6">Table 6</a>. These results reflect centrally adjudicated data after an average follow-up of 5.6 years.</p>
<table width="100%">
<col width="25%">
<col width="25%">
<col width="25%">
<col width="25%">
<tfoot><tr><td colspan="4" align="left"><dl class="Footnote">
<dt><a name="footnote-6" href="#footnote-reference-6">*</a></dt>
<dd>Nominal confidence intervals unadjusted for multiple looks and multiple comparisons.</dd>
<dt><a name="footnote-7" href="#footnote-reference-7">†</a></dt>
<dd>Not included in “global index?.</dd>
<dt><a name="footnote-8" href="#footnote-reference-8">‡</a></dt>
<dd>Includes metastatic and non-metastatic breast cancer with the exception of <span class="Italics">in situ</span> cancer.</dd>
<dt><a name="footnote-9" href="#footnote-reference-9">§</a></dt>
<dd>All <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">deaths</span>, except from breast or colorectal cancer, definite or probable CHD, PE or cerebrovascular disease.</dd>
<dt><a name="footnote-10" href="#footnote-reference-10">¶</a></dt>
<dd>A subset of the events was combined in a “global index? defined as the earliest occurrence of CHD events, invasive breast cancer, <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span>, <span class="product-label-link" type="condition" conceptid="440417" conceptname="Pulmonary embolism">pulmonary embolism</span>, colorectal cancer, <span class="product-label-link" type="condition" conceptid="4138412" conceptname="Fracture of proximal end of femur">hip fracture</span>, or <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> due to other causes. </dd>
</dl></td></tr></tfoot>
<tbody class="Headless">
<tr class="First"><td align="center" colspan="4"><p class="First"><span class="Bold">Table 6. Relative and Absolute Risk Seen in the Estrogen Plus Progestin Substudy of WHI at an Average of 5.6 Years</span><a href="#_Ref395604470">1</a><span class="Bold"><span class="Sup">,</span></span><a href="#_Ref395604480">2</a><br></p></td></tr>
<tr>
<td class="Botrule" rowspan="2"><p class="First">Event</p></td>
<td align="center" rowspan="2">
<p class="First">Relative Risk </p>
<p>CE/MPA vs. Placebo (95 percent nCI<a name="footnote-reference-6" href="#footnote-6" class="Sup">*</a></p>
</td>
<td class="Botrule Toprule" align="center">
<p class="First">CE/MPA</p>
<p>n = 8,506</p>
</td>
<td class="Botrule Toprule" align="center">
<p class="First">Placebo</p>
<p>n = 8,102</p>
</td>
</tr>
<tr><td align="center" colspan="2"><p class="First">Absolute Risk per 10,000 Women -Years</p></td></tr>
<tr>
<td class="Botrule">
<p class="First">CHD events </p>
<p><span class="Italics">Non-fatal MI</span></p>
<p><span class="Italics">CHD <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span></span></p>
<p>All <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">strokes</span></p>
<p><span class="Italics"><span class="product-label-link" type="condition" conceptid="4310996" conceptname="Ischemic stroke">Ischemic stroke</span></span></p>
<p><span class="product-label-link" type="condition" conceptid="4042396" conceptname="Deep thrombophlebitis">Deep vein thrombosis</span><a name="footnote-reference-7" href="#footnote-7" class="Sup">†</a></p>
<p><span class="product-label-link" type="condition" conceptid="440417" conceptname="Pulmonary embolism">Pulmonary embolism</span></p>
<p>Invasive breast cancer<a name="footnote-reference-8" href="#footnote-8" class="Sup">‡</a></p>
<p>Colorectal cancer</p>
<p>Endometerial cancer<a href="#footnote-7" class="Sup">†</a></p>
<p>Cervical cancer<a href="#footnote-7" class="Sup">†</a></p>
<p><span class="product-label-link" type="condition" conceptid="4138412" conceptname="Fracture of proximal end of femur">Hip fracture</span></p>
<p><span class="product-label-link" type="condition" conceptid="4066995" conceptname="Fracture of vertebral column with spinal cord injury">Vertebral fractures</span><a href="#footnote-7" class="Sup">†</a></p>
<p>Lower arm/wrist <span class="product-label-link" type="condition" conceptid="75053" conceptname="Fracture of bone">fractures</span><a href="#footnote-7" class="Sup">†</a></p>
<p>Total <span class="product-label-link" type="condition" conceptid="75053" conceptname="Fracture of bone">fractures</span><a href="#footnote-7" class="Sup">†</a></p>
<p>Overall Mortality<a href="#footnote-6" class="Sup">*</a><span class="Sup">,</span><a name="footnote-reference-9" href="#footnote-9" class="Sup">§</a></p>
<p>Global Index<a name="footnote-reference-10" href="#footnote-10" class="Sup">¶</a></p>
</td>
<td class="Botrule Toprule" align="center">
<p class="First">1.23 (0.99 to 1.53)</p>
<p><span class="Italics">1.28 (1 to 1.63)</span></p>
<p><span class="Italics">1.1 (0.7 to 1.75)</span></p>
<p>1.31 (1.03 to 1.68)</p>
<p><span class="Italics">1.44 (1.09 to 1.9)</span></p>
<p>1.95 (1.43 to 2.67)</p>
<p>2.13 (1.45 to 3.11)</p>
<p>1.24 (1.01 to 1.54)</p>
<p>0.61 (0.42 to 0.87)</p>
<p>0.81 (0.48 to 1.36)</p>
<p>1.44 (0.47 to 4.42)</p>
<p>0.67 (0.47 to 0.96)</p>
<p>0.65 (0.46 to 0.92)</p>
<p>0.71 (0.59 to 0.85)<br></p>
<p>0.76 (0.69 to 0.83)</p>
<p>1 (0.83 to 1.19)</p>
<p>1.13 (1.02 to 1.25)</p>
</td>
<td class="Botrule Toprule" align="center">
<p class="First">41</p>
<p><span class="Italics">31</span></p>
<p><span class="Italics">8</span></p>
<p>33</p>
<p><span class="Italics">26</span></p>
<p>26</p>
<p>18</p>
<p>41</p>
<p>10</p>
<p>6</p>
<p>2</p>
<p>11</p>
<p>11</p>
<p>44<br></p>
<p>152</p>
<p>52</p>
<p>184</p>
</td>
<td class="Botrule Toprule" align="center">
<p class="First">34</p>
<p><span class="Italics">25</span></p>
<p><span class="Italics">8</span></p>
<p>25</p>
<p><span class="Italics">18</span></p>
<p>13</p>
<p>8</p>
<p>33</p>
<p>16</p>
<p>7</p>
<p>1</p>
<p>16</p>
<p>17</p>
<p>62<br></p>
<p>199</p>
<p>52</p>
<p>165</p>
</td>
</tr>
<tr class="Last"><td colspan="4"></td></tr>
</tbody>
</table>
<p>Timing of the initiation of estrogen plus progestin therapy relative to the start of <span class="product-label-link" type="condition" conceptid="4059477" conceptname="Menopause">menopause</span> may affect the overall risk benefit profile. The WHI estrogen plus progestin substudy stratified by age showed in women 50 to 59 years of age, a non-significant trend toward reduced risk for overall mortality <span class="Italics">[hazard ratio (HR) 0.69 (95 percent CI, 0.44 to 1.07)]</span>. <br></p>
<p><span class="Italics">WHI Estrogen-Alone Substudy <br></span></p>
<p>The WHI estrogen-alone substudy was also stopped early because an increased risk of <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span> was observed, and it was deemed that no further information would be obtained regarding the risks and benefits of estrogen-alone in predetermined primary endpoints. <br></p>
<p>Results of the estrogen-alone substudy, which included 10,739 women (average 63 years of age, range 50 to 79; </p>
<p>75.3 percent White, 15.1 percent Black, 6.1 percent Hispanic, 3.6 percent Other), after an average follow-up of </p>
<p>7.1 years, are presented in <a href="#Table_7">Table 7</a>.</p>
<table width="100%">
<col width="25%">
<col width="25%">
<col width="25%">
<col width="25%">
<tfoot><tr><td colspan="4" align="left"><dl class="Footnote">
<dt><a name="footnote-11" href="#footnote-reference-11">*</a></dt>
<dd>Adapted from numerous WHI publications. WHI publications can be viewed at <span class="Underline"><a href="http://www.nblbi.nih.gov/whi">www.nblbi.nih.gov/whi</a></span>.</dd>
<dt><a name="footnote-12" href="#footnote-reference-12">†</a></dt>
<dd>Nominal confidence intervals unadjusted for multiple looks and multiple comparisons.</dd>
<dt><a name="footnote-13" href="#footnote-reference-13">‡</a></dt>
<dd>Results are based on centrally adjudicated data for an average follow-up of 7.1 years.</dd>
<dt><a name="footnote-14" href="#footnote-reference-14">§</a></dt>
<dd>Not included in “global index?.</dd>
<dt><a name="footnote-15" href="#footnote-reference-15">¶</a></dt>
<dd>Results are based on an average follow-up of 6.8 years.</dd>
<dt><a name="footnote-16" href="#footnote-reference-16">#</a></dt>
<dd>All <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">deaths</span>, except from breast or colorectal cancer, definite or probable CHD, PE or cerebrovascular disease.</dd>
<dt><a name="footnote-17" href="#footnote-reference-17">Þ</a></dt>
<dd>A subset of the events was combined in a “global index? defined as the earliest occurrence of CHD events, invasive breast cancer, <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span>, <span class="product-label-link" type="condition" conceptid="440417" conceptname="Pulmonary embolism">pulmonary embolism</span>, colorectal cancer, <span class="product-label-link" type="condition" conceptid="4138412" conceptname="Fracture of proximal end of femur">hip fracture</span>, or <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> due to other causes.</dd>
</dl></td></tr></tfoot>
<tbody class="Headless">
<tr class="First"><td class="Botrule" align="center" colspan="4">
<p class="First"><span class="Bold">Table 7. Relative and Absolute Risk Seen in the Estrogen- Alone</span></p>
<p><span class="Bold">Substudy of WHI</span><a name="footnote-reference-11" href="#footnote-11" class="Sup">*</a><br></p>
</td></tr>
<tr>
<td class="Botrule Toprule" rowspan="2"><p class="First">Event</p></td>
<td class="Botrule Toprule" align="center" rowspan="2">
<p class="First">Relative </p>
<p>Risk CE vs Placebo</p>
<p> (95 percent nCI<a name="footnote-reference-12" href="#footnote-12" class="Sup">†</a>)</p>
</td>
<td class="Botrule Toprule" align="center">
<p class="First">CE</p>
<p>n = 5,310</p>
</td>
<td class="Botrule Toprule" align="center">
<p class="First">Placebo </p>
<p>n = 5,429</p>
</td>
</tr>
<tr><td class="Botrule" align="center" colspan="2"><p class="First">Absolute Risk per 10,000 Women -Years</p></td></tr>
<tr>
<td class="Botrule Toprule">
<p class="First">CHD events<a name="footnote-reference-13" href="#footnote-13" class="Sup">‡</a></p>
<p><span class="Italics">Non-fatal MI</span><a href="#footnote-13" class="Sup">‡</a></p>
<p><span class="Italics">CHD <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span></span><a href="#footnote-13" class="Sup">‡</a></p>
<p>All <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">strokes</span><a href="#footnote-13" class="Sup">‡</a></p>
<p><span class="Italics"><span class="product-label-link" type="condition" conceptid="4310996" conceptname="Ischemic stroke">Ischemic stroke</span></span><a href="#_Ref395703261">3</a></p>
<p>Deep vein</p>
<p><span class="product-label-link" type="condition" conceptid="4130722" conceptname="Thrombosis">thrombosis</span><a href="#footnote-13" class="Sup">‡</a><span class="Sup">,</span><a name="footnote-reference-14" href="#footnote-14" class="Sup">§</a></p>
<p><span class="product-label-link" type="condition" conceptid="440417" conceptname="Pulmonary embolism">Pulmonary embolism</span><a href="#footnote-13" class="Sup">‡</a></p>
<p>Invasive breast</p>
<p>cancer<a href="#footnote-13" class="Sup">‡</a></p>
<p>Colorectal cancer<a name="footnote-reference-15" href="#footnote-15" class="Sup">¶</a></p>
<p><span class="product-label-link" type="condition" conceptid="4138412" conceptname="Fracture of proximal end of femur">Hip fracture</span><a href="#footnote-13" class="Sup">‡</a></p>
<p><span class="product-label-link" type="condition" conceptid="4066995" conceptname="Fracture of vertebral column with spinal cord injury">Vertebral fractures</span><a href="#footnote-13" class="Sup">‡</a><span class="Sup">,</span><a href="#footnote-14" class="Sup">§</a></p>
<p>Lower arm/wrist <span class="product-label-link" type="condition" conceptid="75053" conceptname="Fracture of bone">fractures</span><a href="#footnote-13" class="Sup">‡</a><span class="Sup">,</span><a href="#footnote-14" class="Sup">§</a></p>
<p>Total <span class="product-label-link" type="condition" conceptid="75053" conceptname="Fracture of bone">fractures</span><a href="#footnote-13" class="Sup">‡</a><span class="Sup">,</span><a href="#footnote-14" class="Sup">§</a></p>
<p><span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">Deaths</span> due to other causes<a href="#footnote-15" class="Sup">¶</a><span class="Sup">,</span><a name="footnote-reference-16" href="#footnote-16" class="Sup">#</a></p>
<p>Overall Mortality<a href="#footnote-13" class="Sup">‡</a><span class="Sup">,</span><a href="#footnote-14" class="Sup">§</a></p>
<p>Global Index<a name="footnote-reference-17" href="#footnote-17" class="Sup">Þ</a></p>
</td>
<td class="Botrule Toprule" align="center">
<p class="First">0.95 (0.78 to 1.16)</p>
<p><span class="Italics">0.91 (0.73 to 1.14)</span></p>
<p><span class="Italics">1.01 (0.71 to 1.43)</span></p>
<p>1.33 (1.05 to 1.68)</p>
<p><span class="Italics">1.55 (1.19 to 2.01)</span></p>
<p>1.47 (1.06 to 2.06)<br></p>
<p>1.37 (0.9 to 2.07)</p>
<p>0.8 (0.62 to 1.04)<br></p>
<p>1.08 (0.75 to 1.55)</p>
<p>0.65 (0.45 to 0.94)</p>
<p>0.64 (0.44 to 0.93)</p>
<p>     0.58 (0.47 to 0.72)</p>
<p></p>
<p>     0.71 (0.64 to 0.8)</p>
<p>1.08 (0.88 to 1.32)<br></p>
<p>1.04 (0.88 to 1.22)</p>
<p>1.02 (0.92 to 1.13)</p>
</td>
<td class="Botrule Toprule" align="center">
<p class="First">54</p>
<p><span class="Italics">40</span></p>
<p><span class="Italics">16</span></p>
<p>45</p>
<p><span class="Italics">38</span></p>
<p>                  23<br></p>
<p>14</p>
<p>28<br></p>
<p>17</p>
<p>12</p>
<p>11</p>
<p>35<br></p>
<p>144</p>
<p>53<br></p>
<p>79</p>
<p>206</p>
</td>
<td class="Botrule Toprule" align="center">
<p class="First">57</p>
<p><span class="Italics">43</span></p>
<p><span class="Italics">16</span></p>
<p>33</p>
<p><span class="Italics">25</span></p>
<p>15<br></p>
<p>10</p>
<p>34<br></p>
<p>16</p>
<p>19</p>
<p>18</p>
<p>59<br></p>
<p>197</p>
<p>50<br></p>
<p>75</p>
<p>201</p>
</td>
</tr>
<tr class="Last"><td class="Toprule" colspan="4"></td></tr>
</tbody>
</table>
<p>For those outcomes included in the WHI “global index? that reached statistical significance, the absolute excess risk per 10,000 women-years in the group treated with CE-alone were 12 more <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">strokes</span>, while the absolute risk reduction per 10,000 women-years was 7 fewer <span class="product-label-link" type="condition" conceptid="4138412" conceptname="Fracture of proximal end of femur">hip fractures</span>.<span class="Sup">9 </span>The absolute excess risk of events included in the “global index? was a non-significant 5 events per 10,000 women-years. There was no difference between the groups in terms of all-cause mortality. <br></p>
<p>No overall difference for primary CHD events (nonfatal MI, silent MI and CHD <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>) and invasive breast cancer incidence in women receiving CE-alone compared with placebo was reported in final centrally adjudicated results from the estrogen-alone substudy, after an average follow-up of 7.1 years (see <a href="#Table_7">Table 7</a>). <br></p>
<p>Centrally adjudicated results for <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span> events from the estrogen-alone substudy, after an average follow-up of </p>
<p>7.1 years, reported no significant difference in distribution of <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span> subtype or severity, including fatal <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">strokes</span>, in women receiving CE-alone compared to placebo. Estrogen-alone therapy increased the risk of <span class="product-label-link" type="condition" conceptid="4310996" conceptname="Ischemic stroke">ischemic stroke</span>, and this excess was present in all subgroups of women examined<span class="Sup">10 </span>(see <a href="#Table_7">Table 7</a>). <br></p>
<p>Timing of the initiation of estrogen-alone therapy relative to the start of <span class="product-label-link" type="condition" conceptid="4059477" conceptname="Menopause">menopause</span> may affect the overall risk benefit profile. The WHI estrogen-alone substudy stratified by age, showed in women 50 to 59 years of age a non-significant trend toward reduced risk for CHD <span class="Italics">[HR 0.63 (95 percent CI, 0.36 to 1.09)] </span>and overall mortality <span class="Italics">[HR 0.71 (95 percent CI, 0.46 to 1.11)]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_6085a306-55d1-4c11-9aab-45c08a1b53fe"></a><a name="section-13.6"></a><p></p>
<h2>14.6 Women’s Health Initiative Memory Study</h2>
<p class="First">The WHIMS estrogen plus progestin ancillary study of WHI enrolled 4,532 predominantly healthy postmenopausal women 65 years of age and older (47 percent were 65 to 69 years of age, 35 percent were 70 to 74 years of age, and 18 percent were 75 years of age and older) to evaluate the effects of CE (0.625 mg) plus MPA (2.5 mg) on the incidence of probable <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">dementia</span> (primary outcome) compared to placebo. <br></p>
<p>After an average follow-up of 4 years, the relative risk of probable <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">dementia</span> for CE plus MPA versus placebo was 2.05 (95 percent CI, 1.21 to 3.48). The absolute risk of probable <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">dementia</span> for CE plus MPA versus placebo was 45 versus 22 per 10,000 women-years. Probable <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">dementia</span> as defined in this study included Alzheimer’s disease (AD), <span class="product-label-link" type="condition" conceptid="379778" conceptname="Multi-infarct dementia">vascular dementia</span> (VaD) and mixed types (having features of both AD and VaD). The most common classification of probable <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">dementia</span> in the treatment group and the placebo group was AD. Since the ancillary study was conducted in women 65 to 79 years of age, it is unknown whether these findings apply to younger postmenopausal women <span class="Italics">[see Warnings and Precautions (</span><span class="Italics"><a href="#ID_b6c93caa-3b1a-4955-93b6-2c1d7d79d3e1">5.3</a>), and Use in Specific Populations (<a href="#ID_047b0de5-d7ac-4eb7-b76b-3d20764b0a03">8.5</a>)]</span>. <br></p>
<p>The WHIMS estrogen-alone ancillary study of WHI enrolled 2,947 predominantly healthy hysterectomized postmenopausal women 65 to 79 years of age (45 percent were 65 to 69 years of age; 36 percent were 70 to 74 years of age; 19 percent were 75 years of age and older) to evaluate the effects of daily CE (0.625 mg)-alone on the incidence of probable <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">dementia</span> (primary outcome) compared to placebo. <br></p>
<p>After an average follow-up of 5.2 years, the relative risk of probable <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">dementia</span> for CE-alone versus placebo was </p>
<p>1.49 (95 percent CI, 0.83 to 2.66). The absolute risk of probable <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">dementia</span> for CE-alone versus placebo was 37 versus 25 cases per 10,000 women-years. Probable <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">dementia</span> as defined in this study included AD, VaD and mixed types (having features of both AD and VaD). The most common classification of probable <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">dementia</span> in the treatment group and the placebo group was AD. Since the ancillary study was conducted in women 65 to 79 years of age, it is unknown whether these findings apply to younger postmenopausal women <span class="Italics">[see Warnings and Precautions (</span><span class="Italics"><a href="#ID_b6c93caa-3b1a-4955-93b6-2c1d7d79d3e1">5.3</a>), and Use in Specific Populations (<a href="#ID_047b0de5-d7ac-4eb7-b76b-3d20764b0a03">8.5</a>)]</span>. <br></p>
<p>When data from the two populations were pooled as planned in the WHIMS protocol, the reported overall relative risk for probable <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">dementia</span> was 1.76 (95 percent CI, 1.19 to 2.6). Differences between groups became apparent in the first year of treatment. It is unknown whether these findings apply to younger postmenopausal women <span class="Italics">[see Warnings and Precautions (</span><span class="Italics"><a href="#ID_b6c93caa-3b1a-4955-93b6-2c1d7d79d3e1">5.3</a>), and Use in Specific Populations (<a href="#ID_047b0de5-d7ac-4eb7-b76b-3d20764b0a03">8.5</a>)]</span>.<br></p>
</div>
</div>
<div class="Section" data-sectionCode="34093-5">
<a name="ID_167dc6dc-aac2-42bc-9623-75816d3b9127"></a><a name="section-14"></a><p></p>
<h1>15 REFERENCES</h1>
<dl>
<dt>1.</dt>
<dd>Rossouw JE, et al. Postmenopausal Hormone Therapy and Risk of Cardiovascular Disease by Age and Years Since <span class="product-label-link" type="condition" conceptid="4059477" conceptname="Menopause">Menopause</span>. <span class="Italics">JAMA</span>. 2007;297:1465-1477. </dd>
<dt>2.</dt>
<dd>Hsia J, et al. Conjugated Equine Estrogens and Coronary Heart Disease. <span class="Italics">Arch Int Med</span>. 2006;166:357-365. </dd>
<dt>3.</dt>
<dd>Cushman M, et al. Estrogen Plus Progestin and Risk of <span class="product-label-link" type="condition" conceptid="444247" conceptname="Venous thrombosis">Venous Thrombosis</span>. <span class="Italics">JAMA</span>. 2004;292:1573-1580. </dd>
<dt>4.</dt>
<dd>Curb JD, et al. <span class="product-label-link" type="condition" conceptid="444247" conceptname="Venous thrombosis">Venous Thrombosis</span> and Conjugated Equine Estrogen in Women Without a Uterus. <span class="Italics">Arch Int Med</span>. 2006;166:772-780. </dd>
<dt>5.</dt>
<dd>Chlebowski RT, et al. Influence of Estrogen Plus Progestin on Breast Cancer and Mammography in Healthy Postmenopausal Women. <span class="Italics">JAMA</span>. 2003;289:3234-3253. </dd>
<dt>6.</dt>
<dd>Stefanick ML, et al. Effects of Conjugated Equine Estrogens on Breast Cancer and Mammography Screening in Postmenopausal Women With Hysterectomy. <span class="Italics">JAMA</span>. 2006;295:1647-1657. </dd>
<dt>7.</dt>
<dd>Anderson GL, et al. Effects of Estrogen Plus Progestin on Gynecologic Cancers and Associated Diagnostic Procedures. <span class="Italics">JAMA</span>. 2003;290:1739-1748. </dd>
<dt>8.</dt>
<dd>Shumaker SA, et al. Conjugated Equine Estrogens and Incidence of Probable <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">Dementia</span> and Mild <span class="product-label-link" type="condition" conceptid="443432" conceptname="Impaired cognition">Cognitive Impairment</span> in Postmenopausal Women. <span class="Italics">JAMA</span>. 2004;291:2947-2958. </dd>
<dt>9.</dt>
<dd>Jackson RD, et al. Effects of Conjugated Equine Estrogen on Risk of <span class="product-label-link" type="condition" conceptid="75053" conceptname="Fracture of bone">Fractures</span> and BMD in Postmenopausal Women With Hysterectomy: Results From the Women’s Health Initiative Randomized Trial. <span class="Italics">J Bone Miner Res</span>. 2006;21:817-828. </dd>
<dt>10.</dt>
<dd>Hendrix SL, et al. Effects of Conjugated Equine Estrogen on <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">Stroke</span> in the Women’s Health Initiative. <span class="Italics">Circulation</span>. 2006;113:2425-2434. </dd>
</dl>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="ID_83db2310-5b63-4d24-b084-96db895b4558"></a><a name="section-15"></a><p></p>
<h1>16 HOW SUPPLIED/STORAGE AND HANDLING</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_e6d3716c-4c19-45a6-b925-57b513125abb"></a><a name="section-15.1"></a><p></p>
<h2>16.1 How Supplied</h2>
<p class="First">Jinteli<span class="Sup">®</span><span class="Bold"><span class="Italics"></span></span>(norethindrone acetate and ethinyl estradiol tablets USP) is available as: </p>
<p>1 mg/5 mcg:      White, round, flat-faced, beveled-edge, unscored tablets. Debossed with stylized <span class="Bold">b</span> on one side and <span class="Bold">125</span> on    </p>
<p>                           the other side. Available in:</p>
<dl>
<dt> </dt>
<dd>              Bottle of 90 Tablets 	NDC 0093-<span class="Bold">	3122</span>	-98</dd>
<dt> </dt>
<dd>              5 <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">Blister</span> Cards of 28 Tablets per Carton 	NDC 0093-<span class="Bold">	3122</span>	-42</dd>
</dl>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_8fe7499f-fdcf-467a-b4ee-61add1c85110"></a><a name="section-15.2"></a><p></p>
<h2>16.2 Storage and Handling</h2>
<p class="First">Store at 20º to 25 ºC (68º to 77ºF) [See USP Controlled Room Temperature].</p>
<p>KEEP THIS AND ALL MEDICATIONS OUT OF THE REACH OF CHILDREN. </p>
</div>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="ID_dfac321d-880a-47d1-aae6-f52aef34e3fa"></a><a name="section-16"></a><p></p>
<h1>17 PATIENT COUNSELING INFORMATION</h1>
<p class="First">See FDA-approved patient labeling (Patient Information)</p>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_91d8d48d-8d88-4212-80f6-c9484885dbea"></a><a name="section-16.1"></a><p></p>
<h2>17.1 Abnormal <span class="product-label-link" type="condition" conceptid="4129155" conceptname="Vaginal bleeding">Vaginal Bleeding</span></h2>
<p class="First">Inform postmenopausal women of the importance of reporting abnormal <span class="product-label-link" type="condition" conceptid="4129155" conceptname="Vaginal bleeding">vaginal bleeding</span> to their healthcare provider as soon as possible <span class="Italics">[see Warnings and Precautions (</span><span class="Italics"><a href="#ID_08fd3295-48f2-4e90-b7ac-6b8a20dfa6fc">5.2</a>)]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_7548c535-312a-4b1a-b892-95c42f27d728"></a><a name="section-16.2"></a><p></p>
<h2>17.2 Possible Serious Adverse Reactions with Estrogen Plus Progestin Therapy</h2>
<p class="First">Inform postmenopausal women of possible serious adverse reactions of estrogen plus progestin therapy including <span class="product-label-link" type="condition" conceptid="134057" conceptname="Disorder of cardiovascular system">Cardiovascular Disorders</span>, Malignant Neoplasms, and Probable <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">Dementia</span> <span class="Italics">[see Warnings and Precautions (</span><span class="Italics"><a href="#ID_37d6c252-eb1b-49ec-b65d-5be3dfa48a29">5.1</a>, <a href="#ID_08fd3295-48f2-4e90-b7ac-6b8a20dfa6fc">5.2</a>, <a href="#ID_b6c93caa-3b1a-4955-93b6-2c1d7d79d3e1">5.3</a>)]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_d0b1c448-92c3-45a2-8ca1-c1c3740c6eef"></a><a name="section-16.3"></a><p></p>
<h2>17.3 Possible Less Serious but Common Adverse Reactions with Estrogen Plus Progestin Therapy</h2>
<p class="First">Inform postmenopausal women of possible less serious but common adverse reactions of estrogen plus progestin therapy such as <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="73819" conceptname="Pain of breast">breast pain</span> and <span class="product-label-link" type="condition" conceptid="4082445" conceptname="Tenderness">tenderness</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>. </p>
<p><span class="Bold">TEVA PHARMACEUTICALS USA, INC.</span></p>
<p>North Wales, PA 19454</p>
<p><br>Rev. B 12/2014</p>
</div>
</div>
<div class="Section" data-sectionCode="42230-3">
<a name="ID_ceee6b16-17d2-444e-9dd9-d56e627f0c5a"></a><a name="section-17"></a><p></p>
<h1>Patient Information</h1>
<dl>
<dt> </dt>
<dd>
<span class="Bold">INFORMATION FOR THE PATIENT <br></span>(norethindrone acetate and ethinyl estradiol tablets USP) </dd>
</dl>
<p class="First">Read this Patient Information before you start taking Jinteli and each time you get a refill. There may be new information. This information does not take the place of talking to your healthcare provider about your <span class="product-label-link" type="condition" conceptid="439082" conceptname="Menopausal syndrome">menopausal symptoms</span> or your treatment.<span class="Bold"></span></p>
<table width="100%">
<col width="100%">
<tbody class="Headless"><tr class="First Last"><td class="Botrule Lrule Rrule Toprule">
<p class="First"><span class="Bold">What is the most important information I should know about Jinteli (a combination of estrogen and progestin)?</span></p>
<dl>
<dt>•</dt>
<dd>Do not use estrogens with progestins to prevent heart disease, <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">heart attacks</span>, <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">strokes</span> or <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">dementia</span>                             (decline of brain function). </dd>
<dt>•</dt>
<dd>Using estrogens with progestins may increase your chances of getting a <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">heart attack</span>, <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">strokes</span>, breast cancer, or blood clots. </dd>
<dt>•</dt>
<dd>Using estrogens with progestins may increase your chance of getting <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">dementia</span>, based on a study of women 65 years of age or older. </dd>
<dt>•</dt>
<dd>Do not use estrogen-alone to prevent heart disease, <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">heart attacks</span>, <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">strokes</span> or <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">dementia</span>. </dd>
<dt>•</dt>
<dd>Using estrogen-alone may increase your chance of getting cancer of the uterus (womb). </dd>
<dt>•</dt>
<dd>Using estrogen-alone may increase your chances of getting <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">strokes</span> or blood clots. </dd>
<dt>•</dt>
<dd>Using estrogen-alone may increase your chance of getting <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">dementia</span>, based on a study of women 65 years of age or older. </dd>
<dt>•</dt>
<dd>You and your healthcare provider should talk regularly about whether you still need treatment with Jinteli. </dd>
</dl>
</td></tr></tbody>
</table>
<p><span class="Bold">What is Jinteli? </span></p>
<p>Jinteli is a prescription medicine that contains two kinds of hormones, an estrogen and a progestin. </p>
<p><span class="Bold">What is Jinteli used for? </span></p>
<p>Jinteli is used after <span class="product-label-link" type="condition" conceptid="4059477" conceptname="Menopause">menopause</span> to: </p>
<dl>
<dt>•</dt>
<dd><span class="Bold">Reduce moderate to severe <span class="product-label-link" type="condition" conceptid="4113666" conceptname="Menopausal flushing">hot flushes</span> </span></dd>
</dl>
<p>Estrogens are hormones made by a woman’s ovaries. The ovaries normally stop making estrogens when a woman is between 45 and 55 years old. This drop in body estrogen levels causes the “change of life? or <span class="product-label-link" type="condition" conceptid="4059477" conceptname="Menopause">menopause</span>, the end of monthly menstrual periods. Sometimes both ovaries are removed during an operation before natural <span class="product-label-link" type="condition" conceptid="4059477" conceptname="Menopause">menopause</span> takes place. The sudden drop in estrogen levels causes “surgical menopause?.<br></p>
<p>When estrogen levels begin dropping, some women get very uncomfortable symptoms, such as feelings of warmth in the face, neck, and chest, or sudden intense episodes of heat and <span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">sweating</span> (“hot flashes? or “hot flushes?). In some women the symptoms are mild, and they will not need to take estrogens. In other women, symptoms can be more severe. </p>
<dl>
<dt>•</dt>
<dd><span class="Bold">Help reduce your chances of getting <span class="product-label-link" type="condition" conceptid="80502" conceptname="Osteoporosis">osteoporosis</span> (thin weak bones) </span></dd>
</dl>
<p>If you use Jinteli only to prevent <span class="product-label-link" type="condition" conceptid="80502" conceptname="Osteoporosis">osteoporosis</span> from <span class="product-label-link" type="condition" conceptid="4059477" conceptname="Menopause">menopause</span>, talk with your healthcare provider about whether a different treatment or medicine without estrogens might be better for you. You and your healthcare provider should talk regularly about whether you still need treatment with Jinteli. </p>
<p><span class="Bold">Who should not take Jinteli? </span></p>
<p><span class="Bold">Do not take Jinteli if you have had your uterus (womb) removed (hysterectomy). </span></p>
<p>Jinteli contains a progestin to decrease the chance of getting cancer of the uterus. If you do not have a uterus, you do not need a progestin and you should not take Jinteli. </p>
<p><span class="Bold">Do not take Jinteli if you: </span></p>
<dl>
<dt> </dt>
<dd><dl>
<dt> </dt>
<dd><span class="Bold">have unusual <span class="product-label-link" type="condition" conceptid="4129155" conceptname="Vaginal bleeding">vaginal bleeding</span> </span></dd>
</dl></dd>
</dl>
<p><span class="product-label-link" type="condition" conceptid="4129155" conceptname="Vaginal bleeding">Vaginal bleeding</span> after <span class="product-label-link" type="condition" conceptid="4059477" conceptname="Menopause">menopause</span> may be a warning sign of cancer of the uterus (womb). Your healthcare provider should check any unusual <span class="product-label-link" type="condition" conceptid="4129155" conceptname="Vaginal bleeding">vaginal bleeding</span> to find out the cause. </p>
<dl>
<dt> </dt>
<dd><dl>
<dt> </dt>
<dd>
<span class="Bold">currently have or have had certain cancers</span>. </dd>
</dl></dd>
</dl>
<p>Estrogens may increase the chance of getting certain types of cancers, including cancer of the breast or uterus. If you have or have had cancer, talk with your healthcare provider about whether you should take Jinteli. </p>
<dl>
<dt> </dt>
<dd><dl>
<dt> </dt>
<dd><span class="Bold">had a <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span> or <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">heart attack</span></span></dd>
<dt> </dt>
<dd><span class="Bold">currently have or have had blood clots</span></dd>
<dt> </dt>
<dd><span class="Bold">currently have or have had liver problems</span></dd>
<dt> </dt>
<dd><span class="Bold">have been diagnosed with a <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> disorder</span></dd>
<dt> </dt>
<dd>
<span class="Bold">are allergic to Jinteli or any of its ingredients</span>. </dd>
</dl></dd>
</dl>
<p>See the list of ingredients in Jinteli at the end of this leaflet. </p>
<dl>
<dt> </dt>
<dd><dl>
<dt> </dt>
<dd><span class="Bold">think you may be pregnant</span></dd>
</dl></dd>
</dl>
<p>Jinteli is not for pregnant women. If you think you may be pregnant, you should have a pregnancy test and know the results. Do not take Jinteli if the test is positive and talk to your healthcare provider. </p>
<p><span class="Bold">What should I tell my healthcare provider before I take Jinteli? </span></p>
<p><span class="Bold">Before you take Jinteli, tell your healthcare provider if you: </span></p>
<dl>
<dt> </dt>
<dd><dl>
<dt> </dt>
<dd><span class="Bold">have any unusual <span class="product-label-link" type="condition" conceptid="4129155" conceptname="Vaginal bleeding">vaginal bleeding</span> </span></dd>
</dl></dd>
<dt> </dt>
<dd><span class="product-label-link" type="condition" conceptid="4129155" conceptname="Vaginal bleeding">Vaginal bleeding</span> after <span class="product-label-link" type="condition" conceptid="4059477" conceptname="Menopause">menopause</span> may be a warning sign of cancer of the uterus (womb). Your healthcare provider should check any unusual <span class="product-label-link" type="condition" conceptid="4129155" conceptname="Vaginal bleeding">vaginal bleeding</span> to find out the cause. <dl>
<dt> </dt>
<dd> have any other medical conditions</dd>
</dl>
</dd>
</dl>
<p>Your healthcare provider may need to check you more carefully if you have certain conditions, such as <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span> (<span class="product-label-link" type="condition" conceptid="314754" conceptname="Wheezing">wheezing</span>), <span class="product-label-link" type="condition" conceptid="380378" conceptname="Epilepsy">epilepsy</span> (<span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span>), <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span>, <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine</span>, <span class="product-label-link" type="condition" conceptid="433527" conceptname="Endometriosis">endometriosis</span>, lupus, <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioedema</span> (<span class="product-label-link" type="condition" conceptid="4133326" conceptname="Facial swelling">swelling of face</span> and tongue), or problems with your heart, liver, thyroid, kidneys, or have high calcium levels in your blood. </p>
<dl>
<dt> </dt>
<dd><dl>
<dt> </dt>
<dd><span class="Bold">are going to have surgery or will be on bed rest</span></dd>
</dl></dd>
<dt> </dt>
<dd>Your healthcare provider will let you know if you need to stop taking Jinteli<dl>
<dt> </dt>
<dd><span class="Bold">are breastfeeding</span></dd>
</dl>
</dd>
<dt> </dt>
<dd>The hormones in Jinteli can pass into your breast milk. </dd>
</dl>
<p><span class="Bold">Tell your healthcare provider about all the medicines you take, </span></p>
<p>including prescription and non-prescription medicines, vitamins, and herbal supplements. Some medicines may affect how Jinteli works. Jinteli may also affect how your other medicines work. Keep a list of your medicines and show it to your healthcare provider and pharmacist when you get a new medicine. </p>
<p><span class="Bold">How should I take Jinteli? </span></p>
<dl>
<dt> </dt>
<dd><dl>
<dt> </dt>
<dd>Take Jinteli exactly as your healthcare provider tells you to take it. </dd>
<dt> </dt>
<dd>Take 1 Jinteli tablet at the same time each day. </dd>
<dt> </dt>
<dd>You and your healthcare provider should talk regularly (every 3 to 6 months) about the dose you are taking and whether or not you still need treatment with Jinteli. </dd>
</dl></dd>
</dl>
<p><span class="Bold">What are the possible side effects of Jinteli? </span></p>
<p><span class="Bold">Side effects are grouped by how serious they are and how often they happen when you are treated. </span></p>
<p><span class="Bold">Serious, but less common side effects include: </span></p>
<dl>
<dt> </dt>
<dd><dl>
<dt> </dt>
<dd><span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">heart attack</span> </dd>
<dt> </dt>
<dd><span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span> </dd>
<dt> </dt>
<dd>blood clots </dd>
<dt> </dt>
<dd><span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">dementia</span> </dd>
<dt> </dt>
<dd>breast cancer </dd>
<dt> </dt>
<dd>cancer of the lining of the uterus (womb) </dd>
<dt> </dt>
<dd>cancer of the ovary </dd>
<dt> </dt>
<dd>high blood pressure </dd>
<dt> </dt>
<dd>high blood sugar </dd>
<dt> </dt>
<dd><span class="product-label-link" type="condition" conceptid="192353" conceptname="Disorder of gallbladder">gallbladder disease</span> </dd>
<dt> </dt>
<dd>liver problems </dd>
<dt> </dt>
<dd>changes in your thyroid hormone levels </dd>
<dt> </dt>
<dd>enlargement of benign tumors of the uterus (“fibroids?) </dd>
</dl></dd>
</dl>
<p><span class="Bold">Call your healthcare provider right away if you get any of the following warning signs or any other unusual symptoms that concern you: </span></p>
<dl>
<dt> </dt>
<dd><dl>
<dt> </dt>
<dd>new <span class="product-label-link" type="condition" conceptid="80767" conceptname="Breast lump">breast lumps</span> </dd>
<dt> </dt>
<dd>unusual <span class="product-label-link" type="condition" conceptid="4129155" conceptname="Vaginal bleeding">vaginal bleeding</span> </dd>
<dt> </dt>
<dd>changes in vision or speech </dd>
<dt> </dt>
<dd>sudden new severe <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headaches</span> </dd>
<dt> </dt>
<dd>severe <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pains</span> in your chest or legs with or without <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">shortness of breath</span>, <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span> and <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span> <br>
</dd>
</dl></dd>
</dl>
<p><span class="Bold">Less serious, but common side effects include: </span></p>
<dl>
<dt> </dt>
<dd><dl>
<dt> </dt>
<dd><span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span> </dd>
<dt> </dt>
<dd><span class="product-label-link" type="condition" conceptid="73819" conceptname="Pain of breast">breast pain</span> </dd>
<dt> </dt>
<dd>irregular <span class="product-label-link" type="condition" conceptid="4129155" conceptname="Vaginal bleeding">vaginal bleeding</span> or spotting </dd>
<dt> </dt>
<dd>stomach or <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal cramps</span>, <span class="product-label-link" type="condition" conceptid="442597" conceptname="Swollen abdomen">bloating</span> </dd>
<dt> </dt>
<dd><span class="product-label-link" type="condition" conceptid="133280" conceptname="Alopecia">hair loss</span> </dd>
<dt> </dt>
<dd><span class="product-label-link" type="condition" conceptid="4125002" conceptname="Idiopathic fluid retention">fluid retention</span> </dd>
<dt> </dt>
<dd>vaginal <span class="product-label-link" type="condition" conceptid="432248" conceptname="Opportunistic mycosis">yeast infection</span> <br>
</dd>
</dl></dd>
</dl>
<p>These are not all the possible side effects of Jinteli. For more information, ask your healthcare provider or pharmacist. Tell your healthcare provider if you have any side effects that bother you or does not go away. </p>
<p>Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.</p>
<p><span class="Bold">What can I do to lower my chances of a serious side effect with Jinteli? </span></p>
<dl>
<dt>•</dt>
<dd>Talk with your healthcare provider regularly about whether you should continue taking Jinteli. </dd>
<dt>•</dt>
<dd>If you have a uterus, talk with your healthcare provider about whether the addition of a progestin is right for you. </dd>
<dt>•</dt>
<dd>The addition of a progestin is generally recommended for a woman with a uterus to reduce the chance of getting cancer of the uterus (womb). </dd>
<dt>•</dt>
<dd>See your healthcare provider right away if you develop <span class="product-label-link" type="condition" conceptid="4129155" conceptname="Vaginal bleeding">vaginal bleeding</span> while taking Jinteli. </dd>
<dt>•</dt>
<dd>Have a pelvic exam, breast exam and mammogram (breast x-ray) every year unless your healthcare provider tells you something else. </dd>
<dt>•</dt>
<dd>If members of your family have had breast cancer or if you have ever had <span class="product-label-link" type="condition" conceptid="80767" conceptname="Breast lump">breast lumps</span> or an abnormal mammogram (breast x-ray), you may need to have breast exams more often. </dd>
<dt>•</dt>
<dd>If you have high blood pressure, high <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span> (fat in the blood), <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span>, are overweight, or use tobacco, you may have a higher chance for getting heart disease. </dd>
</dl>
<p>Ask your healthcare provider for ways to lower your chances of getting heart disease. </p>
<p><span class="Bold">How should I store Jinteli?</span></p>
<dl>
<dt> </dt>
<dd><dl>
<dt> </dt>
<dd>Store Jinteli at room temperature between 20° to 25°C (68° to 77°F). <br>
</dd>
</dl></dd>
</dl>
<p><span class="Bold">Keep Jinteli out of the reach of children. </span></p>
<p><span class="Bold">General information about the safe and effective use of Jinteli. </span></p>
<p>Medicines are sometimes prescribed for conditions that are not mentioned in patient information leaflets. Do not take Jinteli for conditions for which it was not prescribed. Do not give Jinteli to other people, even if they have the same symptoms you have. It may harm them. </p>
<p>This leaflet summarizes the most important information about Jinteli. If you would like more information, talk with your healthcare provider or pharmacist. You can ask your pharmacist or healthcare provider for information about Jinteli that is written for health professionals. </p>
<p>For more information call 1-888-838-2872. </p>
<p><span class="Bold">What are the ingredients in Jinteli? </span></p>
<p><span class="Bold">Active Ingredients: </span>norethindrone acetate, USP and ethinyl estradiol, USP </p>
<p><span class="Bold">Inactive Ingredients: </span>calcium stearate, lactose monohydrate, microcrystalline cellulose, pregelatinized corn starch, and sodium starch glycolate</p>
<p><br>This Patient Information has been approved by the U.S Food and Drug Administration. </p>
<p><span class="Bold">TEVA PHARMACEUTICALS USA, INC.</span></p>
<p>North Wales, PA 19454<br></p>
<p>Rev. B 12/2014</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="ID_ec7be300-49fd-457c-b314-cb36e99fe531"></a><a name="section-18"></a><p></p>
<h1>Package/Label Display Panel, Part 1 of 2</h1>
<div class="Figure">
<a name="id1136107256"></a><img alt="Jinteli® (norethindrone acetate and ethinyl estradiol tablets USP) 1 mg/5 mcg Carton Part 1 of 2" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=d667ca75-1a17-43fc-9077-f25ce0908f8d&amp;name=image-06.jpg">
</div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="ID_5e11c957-9ee8-4635-9d67-2d52ab8c333e"></a><a name="section-19"></a><p></p>
<h1>Package/Label Display Panel, Part 2 of 2</h1>
<div class="Figure">
<a name="id-2090826440"></a><img alt="Jinteli® (norethindrone acetate and ethinyl estradiol tablets USP) 1 mg/5 mcg Carton Part 2 of 2" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=d667ca75-1a17-43fc-9077-f25ce0908f8d&amp;name=image-05.jpg">
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_2655d090-a43e-4da9-953d-ac231e93c914"></a><a name="section-19.1"></a><p></p>
<h2>Jinteli® (norethindrone acetate and ethinyl estradiol tablets USP) 1 mg/5 mcg Carton Text</h2>
<p class="First"><span class="Bold">NDC</span> 0093-<span class="Bold">3122</span>-98</p>
<p>90 TABLETS</p>
<p><span class="Bold"><span class="Italics">Jinteli</span>®</span></p>
<p>(norethindrone acetate and </p>
<p>ethinyl estradiol tablets USP)</p>
<p><span class="Bold">1 mg/5 mcg</span></p>
<p><span class="Bold">PHARMACIST: </span>PLEASE DISPENSE WITH PATIENT INFORMATION</p>
<p>LEAFLET</p>
<p><span class="Bold">Rx only</span></p>
<p><span class="Bold">SHAPING </span></p>
<p><span class="Bold">WOMEN’S HEALTH®</span></p>
<p><span class="Bold">TEVA</span></p>
</div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>JINTELI 		
					</strong><br><span class="contentTableReg">norethindrone acetate and ethinyl estradiol tablet</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:0093-3122</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>NORETHINDRONE ACETATE</strong> (NORETHINDRONE) </td>
<td class="formItem">NORETHINDRONE ACETATE</td>
<td class="formItem">1 mg</td>
</tr>
<tr class="formTableRow">
<td class="formItem">
<strong>ETHINYL ESTRADIOL</strong> (ETHINYL ESTRADIOL) </td>
<td class="formItem">ETHINYL ESTRADIOL</td>
<td class="formItem">5 ug</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>CALCIUM STEARATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>LACTOSE MONOHYDRATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>CELLULOSE, MICROCRYSTALLINE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>STARCH, CORN</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SODIUM STARCH GLYCOLATE TYPE A POTATO</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">WHITE</td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">ROUND</td>
<td class="formLabel">Size</td>
<td class="formItem">6mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">b;125</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:0093-3122-98</td>
<td class="formItem">90  in 1 BOTTLE; Combination Product Type = C112160</td>
<td class="formItem">02/17/2011</td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem">NDC:0093-3122-42</td>
<td class="formItem">5  in 1 CARTON</td>
<td class="formItem">02/17/2011</td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem">NDC:0093-3122-28</td>
<td class="formItem">28  in 1 <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">BLISTER</span> PACK; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">ANDA</td>
<td class="formItem">ANDA076221</td>
<td class="formItem">02/17/2011</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>Teva Pharmaceuticals USA Inc
							(001627975)
						</td></tr></table>
</div>
<p><div class="EffectiveDate">Revised: 3/2015<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>b58445af-4180-49b5-a968-86f342a84eb4</div>
<div>Set id: d667ca75-1a17-43fc-9077-f25ce0908f8d</div>
<div>Version: 5</div>
<div>Effective Time: 20150309</div>
</div>
</div> <div class="DistributorName">Teva Pharmaceuticals USA Inc</div></p>
</body></html>
